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Glioblastoma multiforme is the most 
malignant of brain tumours and it is 
one of the most fatal cancers in hu-
mans. This thesis aimed at develop-
ing a new model that would allow for 
tumor debulking and local applica-
tion of therapeutic agents. Addition-
ally, a new treatment approach based 
on 15-lipoxygenase-1 gene transfer 
was studied. The results demonstrat-
ed that it was able to prolong animal 
survival, although it may also induce 
cell migration upon combination with 
HSV-tk gene therapy.
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ABSTRACT
Glioblastoma multiforme (GBM) is the most malignant of brain tumours and in general is
one of the most lethal and refractory cancers in humans, as it is highly resistant to
conventional therapies. Despite advances in surgery, radiation and chemotherapy, the
outcome of GBM remains grim and there is an urgent need to develop alternative means to
treat these brain tumours.
Unfortunately,  translation  of  successful  therapies  from  rodents  to  human  patients  is
complicated as they often fail in clinical trials. Utilizing an animal model that allows
assessing the efficacy of innovative treatment approaches in combination with gross
surgical resection seems to be crucial. However, one of the major obstacles is the lack of an
easily accessible large animal model for testing new treatment regimes in combination with
surgery.
The primary goal of this study was to develop a model that would allow for tumor
debulking and then the local application of therapeutic agents into the walls of the resection
cavity. This study evaluated the usability of VX-2 model for testing novel drugs and
delivery  routes  for  brain  tumours.  Another  goal  was  to  establish  the  first  rabbit
glioblastoma model using lentivirus mediated oncogenesis. As far as we are aware, this is
the  first  time  that  it  has  been  possible  to  induce  rabbit  glioma  with  the  use  of  lentivirus
transduced neural stem cells.
Another goal of this study was to investigate novel gene therapeutic approaches. Gene
therapy is a powerful technique in molecular medicine that allows for treatment of wide
array of diseases, including GBM. The genes inducing apoptosis and inhibiting
angiogenesis in glial cells are of particular interest. 15-lipoxygenase-1 is a multifunctional
enzyme able to produce a vast number of metabolites with diverse bioactivities. It was
proved that 15-lipoxygenase-1 is a promising molecule that is able to inhibit glioblastoma
growth and prolong animal survival. Our results indicated that one possible mechanism of
the anti-tumorigenic potential is promotion of apoptosis via caspase-3 upregulation.
Nonetheless,  when  combined  with  a  commonly  used  suicide  gene  therapy  strategy,  it
induced a shift in glioblastoma tumor phenotype toward enhanced migration and brain
tissue infiltration.
National Library of Medical Classification: WL 358, QZ 380, QY 58, QY 60.L3, QZ 52
Medical Subject Headings: Brain Neoplasms/therapy; Glioma; Glioblastoma; Gene Transfer Techniques; Gene
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TIIVISTELMÄ
Glioblastoma  multiforme  (GBM)  on  kaikkein  pahanlaatuisin  aivokasvain.  Se  on  yksi
vaikeahoitoisimmista syövistä johtuen sen resistenssistä tavanomaisille hoidoille.
Huolimatta kirurgian, sädehoidon ja kemoterapian alalla tapahtuneesta edistyksestä,
GBM:n ennuste on edelleen synkkä ja siksi onkin suuri tarve kehittää uusia keinoja näiden
aivokasvainten hoitoon.
Eläinkokeissa tehokkaiksi osoittautuneiden hoitomuotojen soveltaminen potilaiden
hoitoon on kuitenkin erittäin haasteellista. Olisi tärkeää hyödyntää sellaista eläinmallia,
jonka avulla on mahdollista arvioida sekä innovatiivisten hoitojen että kirurgisen
leikkaushoidon tehokkuutta. Kuitenkin yksi suurimmista esteistä on toistaiseksi ollut se,
ettei saatavilla ole ollut eläinmalleja, joilla voitaisiin testata uusia hoitoja yhdessä
leikkaushoidon kanssa. Tämän tutkimuksen ensisijainen tavoite on ollut kehittää malli, joka
sallisi kasvaimen poiston ja terapeuttisten valmisteiden siirtämisen paikallisesti kasvaimen
leikkausonkaloon. Tutkimus osoitti VX-2 mallin käyttökelpoisuuden aivokasvainten uusien
lääkkeiden ja annostelureittien tutkimuksessa. Se myös pyrki luomaan ensimmäisen kanin
glioblastoomamallin, jossa kasvaimen kehittyminen on saatu aikaan lentiviruksen avulla.
Kyseessä on ensimmäinen tutkimus joka todistaa, että kanille on mahdollista aiheuttaa
gliooma käyttäen lentiviruksella transfektoituja hermon kantasoluja.
Tutkimuksen toinen tavoite on ollut tutkia uusia terapeuttisia geenihoitoja. Geeniterapia
on tehokas molekyylilääketieteen tekniikka, joka mahdollistaa monien eri sairauksien
hoitamisen. GBM:n hoidossa testasimme gliasolujen apoptoosin käynnistämiseen ja
angiogeneesin estämiseen liittyvien geenihoitojen tehoa. Osoitimme, että 15-
lipoksygenaasi-1:n geeninsiirto aivokasvaimeen esti merkittävästi glioblastoomien kasvua
ja pidensi glioblastoomaa sairastavien eläinten elinikää. Tuloksemme viittaavat myös
siihen, että yksi syövän kasvua estävistä mekanismeista on apoptoosi, joka johtuu kaspaasi-
3:n lisääntyneestä  ilmentymisestä. Toisaalta havaittiin, että kun kaspaasi-3:n lisääntyminen
yhdistettiin yleisesti käytettyyn sytotoksiseen geenihoitoon, glioblastooman fenotyyppi
muuttui siten, että kasvain kykeni helpommin leviämään aivoalueelta toiselle. Vaikka
geenihoitojen optimointia edelleen tarvitaan ennen uusiin potilaskokeisiin siirtymistä,
väitöskirjatyössä tutkitut uudet hoitogeenit antavat tulevaisuudessa uusia mahdollisuuksia
pahanlaatuista aivokasvainta sairastavien potilaiden hoitoon.
Luokitus: WL 358, QZ 380, QY 58, QY 60.L3, QZ 52
Yleinen Suomalainen asiasanasto: aivot; aivosairaudet; kasvaimet; gliooma; hoitomenetelmät; geeniterapia;
adenovirukset; lentivirukset; kantasolut; eläinkokeet; koe-eläimet; rotat; kaniinit
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1 Introduction
Cancer is the generic term for a group of diseases that are featured with uncontrolled
growth and spread of abnormal cells and is an alarming problem worldwide. Glioblastoma
multiforme  (GBM)  is  the  most  malignant  of  brain  tumours  and  one  of  the  most  fatal  and
refractory cancers suffered by humans, as it is highly resistant to conventional therapies.
Despite the advances in surgery, radiation and chemotherapy, they have resulted in only
marginal clinical improvements and the final outcome remains dismal, with average
survival of a mere 14.2 months (Stupp et al. 2005a). At present, there is no curative
treatment  for  GBM,  and  thus  there  is  an  urgent  need  to  develop  alternative  means  of
treatment.
Unfortunately,  translation  of  successful  therapies  from  rodents  to  human  patients  is
complicated as they often fail in clinical trials. This may be partially attributable to the
animal models which insufficiently reflect the clinical reality in human patients. It is
essential to develop a model that would allow for tumour debulking and local application
of therapeutic agents into the walls of the resection cavity. Thus, larger animal models
would be valuable for testing innovative treatments and local drug application routes.
A  further  crucial  issue  for  successful  translation  of  novel  therapeutics  is  malignant  cell
infiltration into surrounding healthy tissue that prevents total surgical debulking. Invasive
cells, which are characterized by high plasticity and resistance to therapies, will often give
rise to a recurrent tumour in patients leading to a fatal outcome. At present it is uncertain to
what extent current therapies are able to reach those cells. Shortage of modelling systems
that reflect the invasive processes in the brain while allowing at the same time for their
direct targeting is a severe problem. It is tempting to speculate that the future of tumor
therapies may lie in targeting these migratory cell populations but this can only be achieved
by developing a model that allows for tumour cavity exposure and treatment of the wound
bed.
Gene therapy is a powerful technique in molecular medicine since it permits the
treatment of wide array of diseases, including GBM. The genes involved in inducing
apoptosis and inhibiting angiogenesis in glial cells are of particular interest. 15-
lipoxygenase-1 (15-LO-1) is a multifunctional enzyme able of synthesizing a vast number of
compounds with a wide variety of bioactivities. A recent report from Viita and coworkers
(Viita et al. 2009) claimed that 15-LO-1 was able to prevent induced neovascularisation in
rabbit eyes and could be used as a potential anti-angiogenic treatment strategy. Other
reports suggest a critical role of 15-LO-1 and its metabolites in inducing apoptosis (Kim et
al. 2006, Sasaki et al. 2006, Wu et al. 2003, Shureiqi et al. 2001). Moreover, the levels of 15-
LO-1 expression have been examined in a variety of normal and cancer tissues; it seems
that they are significantly reduced in many carcinomas (Kim et al. 2006, Sasaki et al. 2006,
Wu et al. 2003, Shureiqi et al. 2001). The loss of expression during cancer progression may
indicate that 15-LO-1 possesses anti-tumourigenic properties and therefore is suppressed in
the process of carcinogenesis. Thus, it could be a promising molecule to be tested for cancer
gene therapy.
2
32 Review of the literature
Cancer is the generic term for a group of diseases that are characterized by uncontrolled
growth and the spread of abnormal cells. It is currently a leading cause of death worldwide.
The World Health Organization (WHO) Cancer Fact Sheet (No°297) states that in 2008 there
were 7.6 million cancer deaths, accounting for approximately 13% of all mortalities/year.
Moreover, the numbers will continue to grow and it is predicted that in the year 2030
there will be over 11 million cancer deaths worldwide
(http://www.who.int/mediacentre/factsheets/fs297/en/).
Cancer  begins  from  a  single  cell  and  its  transformation  is  driven  by  an  interplay  of
environmental and genetic factors. Cancers are heterogeneous and complex tissues, which
maintain the ability for uninterrupted functioning despite being exposed to a wide range of
external and internal stresses. They are composed of multiple distinct cells involved in
heterotypic interactions between each other as well as of normal cells, which form tumour-
associated stroma and which actively participate in tumourigenesis. Cancers are able to
sustain their proliferation even when under constant pressure from their microenvironment
and the body’s immune system and they constantly adapt to the novel changes that they
encounter. In their milestone review, Hanahan and Weinberg identified six hallmarks of
cancer,  which  list  the  newly  obtained  properties  that  allow  cancer  to  survive  and  further
expand (Hanahan, Weinberg 2000). Those modifications include self-sufficiency in growth
signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death,
limitless replicative potential, sustained angiogenesis and tissue invasion and metastasis. In
their recent review, they have also characterized two other emerging hallmarks – the ability
to evade immune destruction and their capacity for reprogramming energy metabolism.
The acquisition of those features is made possible by two so called enabling characteristics,
namely the development of genetic instability and the triggering of tumour-promoting
inflammation (Hanahan, Weinberg 2011).
The incredible ability of cancer to maintain heterogeneity and withstand environmental
stress represents the main hurdle in their management and poses a serious problem in
designing successful therapeutics. The constantly increasing knowledge of their biology is
helping to identify new ways to control their growth and improving the survival of some
patients with many common cancers, such as breast cancer. Unfortunately, we continue to
fail in battling other types, such as malignant gliomas, where the prognosis for the patient
remains grim and there is an urgent need to design a novel, potent therapy to successfully
treat the continuously increasing number of patients with this disease.
2.1 GLIOMA
Glial  tumours  are  believed  to  arise  from  neuroepithelial  tissue  and  can  be  classified  into
astrocytic, oligodendroglial and oligoastrocytic tumours. Astrocytomas, composed
predominantly of neoplastic astrocytes, account for 80% of all gliomas. Gliomas are
classified not only according to their degree of differentiation but they are also
subsequently graded, depending on the degree of malignancy. The most widely recognized
scale is the WHO classification and grading system of tumours affecting the central nervous
system (Louis, World Health Organization & International Agency for Research on Cancer
2007), where astrocytomas with malignant scores I and II are termed low grade whereas those
with scores III and IV are termed high grade tumours. Grade I lesions (pilocytic astrocytomas)
are rare tumours with a low proliferative potential which can be cured by surgery alone.
Pilocytic astrocytomas occur mostly in children, while grade II-IV tumours are found
mostly in adults. Grade II tumours like diffuse astrocytoma are characterised by nuclear
4atypia and a tendency to recur, which may lead to further progress into higher grades of
malignancy. Anaplastic astrocytoma is a grade III neoplasm that is malignant and usually
leads to death within a few years, despite radio- and chemotherapy. Finally, grade IV
tumours, are highly malignant, mitotically active and necrosis-prone neoplasms with rapid
disease progression that leads to fatal outcome.
2.1.1 Glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most malignant of brain tumours as well as one of
the most fatal and refractory cancers in humans. It accounts for 12-15% of all intracranial
neoplasms and 60-75% of astrocytic tumours (Ohgaki, Kleihues 2005). Glioblastoma
multiforme  most  typically  affects  adults  and  is  most  commonly  located  in  deep  white
matter of cerebral hemispheres, what is often manifested with seizures followed by
headache, nausea or neurological changes (Louis, World Health Organization &
International Agency for Research on Cancer 2007).
Figure  1.   61-year-old  patient  with  a  few  weeks  history  of  headache,  confusion  and  a  slight
visual field defect on the left side. T1 gadolinium enhanced axial images showing large necrotic
right temporal lobe glioblastoma (A, B). The tumour is growing over the midline in the region of
the splenium (A). Immediate post operation T1 gadolinium enhanced axial images (C, D). The
large temporal lobe tumour mass has been resected (D), but the part of the tumour growing in
right  atrium  and  in  the  splenium  could  not  be  removed  (C).  Pictures  kindly  provided  by  Arto
Immonen MD, PhD; Dept. of Neurosurgery, Kuopio University Hospital.
The aetiology of primary brain tumours is still unknown and risk factors are poorly defined.
Unfortunately, in spite of progress in surgery, radiotherapy and chemotherapy techniques,
the overall survival of GBM patients remains poor. Retrospective population-based studies
have revealed that less than 20% of patients live longer than one year and less than 3%
survived more than 3 years (Ohgaki, Kleihues 2005, Ohgaki et al. 2004). Thus, it is clear that
there is a great need for novel treatment strategies that would improve the outcome of
glioblastoma multiforme patients.
The cellular origins of GBM tumours remain enigmatic. For many years it was thought
that malignant transformation was driving the de-differentiation of astrocytes. However,
5recently increasing evidence has accumulated that the tumourigenesis starts from the
malignant transformation of precursor cells (Wren, Wolswijk & Noble 1992) or neural stem
cells (Mayer-Proschel et al. 1997). This concept was further supported by the isolation of
cells with stem cell-like properties from tumours. In parallel, Phillips and co-workers
discovered a substantial overlap between the gene-expression profiles of high-grade
gliomas and progenitor cells present in the developing brain (Phillips et al. 2006). Thus, the
cellular, biochemical and genetic heterogeneity that characterises glioblastoma multiforme
could be easily explained as stem like cells not only have a high proliferative potential and
migratory abilities but also can pursue remarkably diverse paths of differentiation. Since
the cancer stem cells provide a reservoir of cells with self-renewal capabilities, they can
maintain tumour growth and are responsible for recurrences after surgical debulking. It is
believed that the extensive and disorganised blood vessel formation that occurs during
tumourigenesis provides niches for support of cancer stem cells (Calabrese et al. 2007).
Another interesting observation evoked an even more exciting possibility. The research on
systemic precursor cells has revealed that they are able to differentiate along
neuroectodermal tracts which raises the possibility that stem cells could undergo
oncogenesis elsewhere and then proliferate within the favourable niche (Mezey et al. 2000).
One of the fundamental features of malignant glioma is tumour necrosis and its presence
is one of the most powerful predictors of aggressive clinical behaviour of those tumours
(Homma et al. 2006, Raza et al. 2002). It is believed that the necrotic areas result from
insufficient blood supply due to rapid, uncontrolled growth. A common histological
hallmark of malignant glioma is the pseudopalisading pattern of necrosis. The connection
between pseudopalisading necrosis and the large regions of confluent necrosis are not clear,
a sequential order has however been postulated where small clusters of apoptotic cells lead
to pseudopalisading necrosis and then further to large areas of ischaemic necrosis (Louis,
World Health Organization & International Agency for Research on Cancer 2007).  Some
researchers consider that the microscopic vaso-occlusions, thrombosis and subsequent
hypoxia are the reasons for induced cell migration and the formation of pseudopalisading
structures (Rong et al. 2006). Hypoxia has also been considered to be a major driving force
of glioblastoma angiogenesis. Glioblastomas are among the most vascularised tumours in
humans  and  thus  the  presence  of  microvascular  proliferation  is  one  of  their  histological
hallmarks (Louis, World Health Organization & International Agency for Research on
Cancer 2007). In general, the proliferative activity with detectable mitoses is high in GBM.
However, interestingly, no clear association between proliferation index and clinical
outcome has been demonstrated (Moskowitz, Jin & Prayson 2006).
In summary, glioblastoma multiforme is highly resistant to any conventionally applied
therapy and at the moment there is no curative treatment available. Unfortunately, the
median survival rate has not improved in recent years, despite the introduction of novel
treatment approaches. According to WHO, there are five main reasons accounting for the
therapeutic resistance to aggressive treatments. One of the most important problems when
it comes to combating GBMs is the vast genotypic and phenotypic heterogeneity. In clinical
terms,  this  means  that  genetic  heterogeneity  is  a  major  cause  of  acquired  drug  resistance
and that the survival of only very small subpopulation of cancer cells may still give rise to
regrowth of tumour or its metastasis. Another very important factor that contributes to
cellular heterogeneity is the presence of highly undifferentiated cells as well as cancer stem
cells  that  most  probably  harbour  resistance  mechanisms.  Moreover,  the  malignant  cells
have highly invasive properties that allow them to infiltrate into healthy tissue, as much as
several  centimetres  away  from  the  bulk  tumour.  Another  obstacle  that  leads  to  poor
response to different treatments is the blood-brain barrier that is known to greatly reduce
access of drugs to the brain. And last but not least, withdrawal of DNA repair system that
abrogates the effectiveness of chemo- and radiotherapy is the fifth main reason why
glioblastomas are characterised by their ease of treatment evasion (Louis, World Health
Organization & International Agency for Research on Cancer 2007).
6Figure  1.  Glioblastoma multiforme at low magnification (A). Geographic necrosis and strong
endothelial proliferation are visible. Cellularity is high, nuclear atypia is clear (B, C). Pictures
kindly provided by Jaana Rumukainen MD, PhD; Dept. of Pathology, Kuopio University Hospital.
2.1.2 Conventional treatments for glioblastoma
Conventional therapy consists of surgical debulking that can be followed by radiotherapy
and/or chemotherapy.
72.1.2.1 Surgery
Currently, surgery is the mostly extensively used means for palliative treatment since it
relieves classic symptoms of brain tumours such as headaches, vomiting and consciousness
problems, however there are also survival benefits reported with maximum prolongation of
life estimated at 4 months (Lacroix et al. 2001).
Conventionally, tumour is debulked from within until visually normal brain is reached.
However,  as  the  glial  cells  tend  to  infiltrate  the  healthy  tissue,  giving  rise  to  a  recurrent
tumour, it is obvious that this kind of strategy is inefficient and unreliable. As it is believed
that the patient outcome is best when the resection is near-total, novel technologies have
been developed to widen the resection margin and allow for more aggressive surgery in the
eloquent cortex. One of the most dramatic but feasible interventions developed at Mayo
Clinic is awake craniotomy, an approach which helps to reduce the risk to vital areas. Local
electrical simulation is applied to determine brain activity and verify the areas that are
amenable for resection (Meyer et al. 2001). Another promising technique for the
optimisation of surgery in malignant gliomas is fluorescence-guided surgery. Fluorescence
is visible when the glial cells take up preoperatively administered 5-aminolevulinic acid
and transform it into protoporphyrin IX (Stummer et al. 1998). As shown by Stummer et al.
this technique allows tumour margins to be resected with higher precision. In a randomised
controlled phase 3 trial on primary malignant gliomas, fluorescence-guided surgery
achieved not only to significantly higher amount of complete resections (65%) as compared
with the conventional operations (36%) but also significantly prolonged 6-month
progression free survival (41% versus 21%, respectively) (Stummer et al. 2006).
Nevertheless, it is important to understand that even conventional, imperfect resections
may be advantageous, as it appears that the space obtained, provoked the tumour to enter
the cell cycle, what makes it more likely to respond to radiation and chemotherapy.
2.1.2.2 Radiotherapy
Radiotherapy is widely accepted and effective early postoperative treatment of choice for
GBM patients. The immediate treatment initiation is important as it has been shown that an
8 week delay as compared with 2 weeks reduces median survival by 11 weeks on average
(Irwin et al. 2007). It is believed that local field irradiation (tumour area with 1.5-2.0 cm
safety margins) is as appropriate as whole-brain radiotherapy and that a total dose of 60 Gy
is better than lower doses (Walker, Strike & Sheline 1979, Bleehen, Stenning 1991). Further
dose escalation have not demonstrated any benefit but did increase the incidence of brain
injury (Nieder et al. 2004). As one of the concerns is the possibility of damaging healthy
tissue, many techniques have been developed that focus on targeting the affected area.
Stereotactic  radiosurgery  may  serve  both  as  an  adjuvant  to  surgical  resection  or  as  a
primary treatment particularly for unresectable tumours or metastatic lesions. For example,
CyberKnife®, a frameless image-guided radiosurgery system, is able to efficiently deliver
the selected radiation beams at submillimeter accuracy thanks to the knowledge of the
patient's unique cranial anatomy (Dieterich, Gibbs 2011, Fukuda et al. 2011). The primary
limitation to glioblastoma radiotherapy however, is the radiation tolerance of normal brain
tissue that may be below the threshold required to kill malignant cells. Glial cell
invulnerability may contribute to their inherent radioresistance. Curently, there are
numerous studies focused on developing sensitizers which would increase impact of the
radiation (Chu et al. 2011, Coupienne et al. 2011, Hiramatsu et al. 2011).
2.1.2.3 Chemotherapy
Until recently, chemotherapy was considered an inefficient treatment for patients with
glioblastoma,  mainly  because  the  blood-brain  barrier  was  assumed  to  represent  a
substantial obstacle to the delivery of therapeutic molecules. Nowadays, however, with
some of the recent clinical success, novel chemotherapeutics have gathered positive
attention. The greatest interest has been focused on cytotoxic agents as they are very
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within the CNS are post-mitotic, thus chemotherapeutic agents with a preferential action on
dividing cells can be relatively tumour-selective.
At present, Temozolomide is the chemotherapeutic drug of choice in GBM treatment.
Not only it is well absorbed orally and easily crosses the blood-brain barrier, but it is very
well tolerated with low neurotoxicity being reported. The standard chemotherapy starts on
the first day of radiation and is maintained throughout its whole duration at 75mg/m2
(Stupp et al. 2002). The adjuvant treatment begins four weeks after the termination of
radiotherapy  and  consists  of  5  day  cycles.  In  the  first  cycle,  the  daily  dose  consists  of
150mg/m2 of temozolomide. The next cycle begins on day 28 with a dosage of 200mg/m2
and  this  regimen  is  continued  for  6  more  cycles.  The  patients  from  this  study  responded
with a significantly longer median survival (14.6 vs. 12.1 months). Additionally, after one
year of follow up, 58% and after 2 years 31% of the patients had a median survival of 16
months (Stupp et al. 2005a, Stupp et al. 2002). A phase III clinical trial proved that the
combination of temozolomide and radiotherapy was superior to radiotherapy alone in
GBM patients (Stupp et al. 2005b).
Interestingly, it has become clear that tumour genotype has a profound effect on
treatment outcome also in the case of temozolomide. Tumour samples from the above
study  were  further  analyzed  and  it  was  shown  that  the  most  powerful  factor  influencing
treatment response was the extent of methylation of the DNA repair enzyme
methylguanine methyltransferase (Hegi et al. 2005). This enzyme is thought to exert its
negative effect by reversing the product of alkylating agents. In combined treatment of
temozolomide and radiation, patients with methylation of the methylguanine
methyltransferase promoter enjoyed a much better survival rate than those who were not
characterised with epigenetic silencing (46% vs. 14%).
These excellent results and the good toxicity profile of temozolomide triggered further
studies investigating the possibilities of using the drug in combination with other
chemotherapeutics (Dixit et al. 2011, McGirt, Brem 2010, Noel et al. 2011) or monoclonal
antibodies (Lai et al. 2011). There is further interest in improving delivery methods for
chemotherapeutics. Despite their low neurotoxicity, it is beneficial to shift from systemic
treatment to more tumour focused therapy. There are numerous reports on novel local
delivery methods such as intratumourally inserted biodegradable wafers (Recinos et al.
2010) or intracranial microcapsules (Scott et al. 2011).
2.2 MALIGNANT GLIOMA ANIMAL MODELS
Modeling cancer in animals is a basic premise for successful implementation of innovative
treatment protocols. There is remarkable potential in the rapidly growing gene therapy
field for glioblastoma, however unfortunately it has not yet been proven to be a success
story in terms of therapeutic outcomes. There are numerous experimental trials that have
been conducted on animal models that seem to hold a great promise for malignant glioma
treatment (Germano, Binello 2009).  Nevertheless, in clinical practice there are substantial
obstacles to be overcome. Currently, only a few protocols have been adopted in human
studies and even then with varying results. The rate limiting steps for successful gene
therapy for brain tumours can be traced to the efficiency, stability and safety of viral vectors.
However, it is also believed that one of the greatest shortcomings originates from the lack
of accurate animal models that not only recapitulate key features of the disease but also are
able to reproduce the treatment regimes being applied in clinics.
2.2.1 Rodent malignant glioma models
There are several mechanisms to generate experimental gliomas in rodents. Primarily brain
tumours have been obtained by treating animals with DNA alkylating agents that generate
point mutations (Barth 1998). The major advantage of these systems is that the histology of
9the lesions bears similarities to human GBM. However, since those changes derive from
untargeted primary mutations, it is not possible to determine which mutation is primarily
responsible for the tumourigenesis. Other advantages of those models are their high
reproducibility, fast in vivo growth rates, accurate knowledge of the tumour location and
last but not least some of them offer the absence of immunogenicity, what makes them
excellent  for  studying  the  response  of  brain  tumours  to  immunotherapy  (Candolfi  et  al.
2007a).
Table 1. Features of intracranial xenograft and syngeneic GBM rodent models and spontaneous
dog GBM (modified from (Candolfi et al. 2007a)).
Tumour biology Dog Rat Mouse
Human in
mouse
Tumour establishment Spontaneus Syngenic Syngenic Xenograft
Allows in vivo imaging + + + +
Allows study of anti-tumoral immune responces + + + -
Allows study of human-targeted therapies - - - +
Reproducible tumour growth rates - + + +/-
Availability - + + +
Cost High Low Low Low
Allows evaluation of large number of animals - + + +
CNS-1 rat glioma is one of the most commonly used rodent models. It was derived from
an inbred Lewis rat that received weekly injections of methyl-nitroso-urea for 6 months
(Laerum, Rajewsky 1975). Histologically, the tumour is characterised by hypercellularity,
nuclear  atypia,  invasiveness  and necrotic  foci  surrounded by pseudopalisading cells.  Like
human GBM, these tumours are infiltrated with macrophages and T-cells, yet they lack
extensive endothelial proliferation (Candolfi et al. 2007a). The CNS-1 model has been
utilised in glioma invasion studies (Owens et al. 1998), gene therapy (Biglari et al. 2004) and
immunotherapy (Ali et al. 2004). Another rat model presenting invasive features is the
BT4C glioma, which was obtained by delivering a single transplacental administration of
N-ethyl-N-nitrosourea to pregnant BDIX rats (Laerum, Rajewsky 1975). It shows high
cellularity with numerous mitotic features and a mixture of multipolar glia-like cells and
flattened cells as well as occasional giant cells (Laerum et al. 1977). It has been tested for
anti-angiogenic agents (Huszthy et al. 2006), suicide gene therapy (Sandmair et al. 1999b)
and chemotherapeutic targeting strategies (Wibom et al. 2010). The 9L gliosarcoma model
has also been widely utilised in therapeutic research despite the sharply delineated tumour
margins (Barth, Kaur 2009). Investigations that have used this model involved research into
anti-angiogenic drugs (Quarles, Schmainda 2007), gene therapy (Mori et al. 2010),
immunotherapy (Ghulam Muhammad et al. 2009) and oncolytic viral therapy (Kramm et al.
1996).  Importantly,  it  must  be  highlighted  that  this  model  was  found  to  be  highly
immunogenic (Morantz et al. 1979, Denlinger et al. 1975). It is now acknowledged that the
in vivo HSV-tk bystander effect (Chen et al. 1995), observed in the 9L model, is partially due
to the anti-tumour immune response (Barth, Kaur 2009). Finally, a widely used model in
experimental neuro-oncology is the C6 rat glioma, which is also known to be immunogenic.
The tumours arose in outbred Wistar rats and have been demonstrated to be immunogenic
in both Wistar and BDIX rats (Parsa et al. 2000). It is crucial to understand both the
advantages and limitations of each of these animal models. Inappropriate study designs
may lead to  false  results  as  in  the  case  where  the  origin  of  the  model  was  not  recognised
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and BDIX rats bearing C6 gliomas were reported to be resistant to both s.c. and i.c.
challenge of the C6 glioma after anti-sense IGF-1 transfection (Parsa et al. 2000).
Another  method  widely  used  in  preclinical  trials  is  the  generation  of  models  by
xenograft transplantation into immune-compromised animals. Similarly to the previous
technique, both cells of origin and the genetic modification remain unknown. These models
seem unlikely to be good predictors of response in humans, yet they are used commonly in
therapeutic testing.  Human xenografts,  based on the intracerebral implantation of human
brain tumour cell lines into immunologically deficient rodents, have been extensively used
to test GBM targeted gene therapies, for example conditionaly replicating oncolytic viruses
(Aghi, Rabkin & Martuza 2006, Jiang et al. 2005, Samoto et al. 2002). Moreover, the
profusely vascularised U-87 model has been also widely applied in GBM angiogenesis
research (Kirsch et al. 1998, Lund, Bastholm & Kristjansen 2000, Schmidt et al. 2004). The
major advantage of xenograft models is that the cancers are of human origin. They also
retain the GBM gene amplifications detected in the in situ tumours (Sarkaria et al. 2006).
However, the major drawback of those models is the impairment of immune-mediated
events that occurs during tumourigenesis and cancer therapies. This factor greatly limits
the usefulness of those models in testing of novel treatments. Another problem that applies
to both syngeneic and xenograft models is that the cells removed from their histological
niche become immunologically different compared to those tested immediately ex vivo.
Expression profiling of  patient  tumours  vs.  corresponding cell  cultures  revealed extensive
changes in gene expression (Li et al. 2008). The differences in MHC and FasL expression
and cytokine production are seen as soon as the first passage in vitro (Anderson et al. 2002).
Interestingly, changes in cell phenotypes were reported as well as in vivo during passaging
in a nude rat brain tumour model established from human biopsies (Wang et al. 2009). The
first generation tumours duplicated the invasive features of the patient tumours, apart from
angiogenesis and necrotic areas. On the contrary, the late generation tumours fulfilled all of
the diagnostic criteria of human GBM, but grew less invasively. The tumours had a higher
cell density and the cells themselves were more malignant in comparison to both first
generation tumours as well as those found in biopsies from patients. Even though this
model provides an excellent tool to investigate the mechanisms driving GBM invasiveness
and angiogenesis, it also draws attention to the problem of cell line alterations both in vitro
and in vivo. To summarize, the cell line based models, unlike the models based on biopsy
spheroids or stem cell like models, not only do not correspond to the genetic profile of the
patient, but most importantly do not possess the highly invasive properties of gliomas.
Thus, in this respect the biopsy spheroid based models or stem cell like models better
represent the tumours in actual patients with regard to invasion (Lee et al. 2006,
Sakariassen et al. 2006).
It is also possible to create GBM models with defined genetics. This goal can be achieved
by two strategies, namely germline or somatic cell mutations. The germline modifications
can help in understanding the roles of gain-of-function and loss-of-function mutations in a
controlled environment. They are known to alter gene expression in large numbers of cells.
Gliomas, however, arise only in a certain percentage of animals, thus it is probable that the
secondary mutations required for actual tumour initiation occur in a limited number of
cells. Therefore, germline mutation models are useful in identifying mutations that
contribute  to,  but  in  themselves  are  insufficient  for  tumourigenesis  (Hu,  Holland  2005).
Until recently, in most of those animal models, either the oncogene has been expressed in
all of the cells in the tissue or a gene has been knocked out in all of the tissue, yet in reality,
cancers arise from a single cell or small numbers of cells. Therefore, somatic cell
modification models are closer to reality in this respect. Marumoto and co-workers have
shown that it is possible to create a murine model where oncogenes are directly transduced
into a small number of cells. The combined activation of H-Ras and Akt and the loss of p53
in GFAP positive cells in the hippocampus or subventrical zone allow the formation of
GBM-like tumours. (Marumoto et al. 2009). Another somatic cell-gene-transfer system uses
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avian leukosis virus (ALV)-based replication incompetent virus to transfer genes to specific
cell types (Holland et al. 1998, Holland, Varmus 1998). It consists of two parts, ALV-based
RCAS vectors and transgenic mice that express the RCAS receptor, tv-a, from a tissue-
specific promoter. The gene transfer in this system is limited to those cells that utilize the
transgene promoter, in the case of brain tumours the astrocyte-specific GFAP promoter or
the CNS progenitor- specific one – nestin. Nevertheless, the defined genetics models of
GBM have limited applications in therapeutic testing. Brain tumours in GBM patients
develop from multiple changes in diverse cellular pathways. This feature may complicate
the translation of therapy outcomes from the above mentioned models to humans.
As the various rodent models are widely accessible and relatively cheap and
undemanding, it makes them a useful screening model for novel therapies in vivo. However,
even though they exhibit similar histopathological features to human GBM, the level of
invasion  is  both  qualitatively  and  quantitatively  different  than  in  humans,  particularly  in
cell-line  based  models.  Additionally,  the  size  of  tumours  and  brains  of  routinely  used
rodent models in comparison to humans varies by several orders of magnitude which
makes them impractical for predicting adequate drug concentrations and makes resection
particularly challenging, even impossible. Thus, the translational potential of rodent GBMs
in the development of novel therapeutic approaches remains challenging.
2.2.2 Large animal malignant glioma models
There is no doubt that large animal brain tumour models would facilitate research on
targeting invading cells that cannot be reached by means of standard resection as well as
novel delivery methods.
Dogs are exceptional large preclinical models that have been shown to be a very valuable
tool in testing efficacy and toxicity of novel therapeutics. They have been proven to be
feasible for therapeutic gene delivery both with non-viral vectors (Oh et al. 2007), as well as
with the most commonly used viral vectors such as adenoviruses (Candolfi et al. 2007b,
Candolfi et al. 2007c) and AAVs (Ciron et al. 2006). Spontaneous GBM in dogs is very
similar to its human counterpart with respect to clinical signs as well as prognosis and
treatment. The standard care also consists of surgical resection, radio- and chemotherapy.
Canine  GBM  is  characterised  with  similar  pathophysiological  features  as  found  in  the
human tumours such as necrosis with pseudopalisading, neovascularisation, endothelial
proliferation and most importantly profound invasion (Candolfi et al. 2007a). Moreover, the
relatively large brain size allows for assessment of doses and the volumes needed to
achieve a therapeutic effect as well as the prediction of therapy-induced toxicity and side
effects. Due to those features, dogs are a very attractive model to test and optimize novel
treatment regimes. However, recruitment of sufficient research cohorts in veterinary clinics
can be complicated due to the low incidence of spontaneous canine brain tumours.
Additionally, the tumour formation rate is variable and the latency is long, what makes the
spontaneous dog GBM not feasible for routine testing.
The lack of easily available large animal model of GBM may be one of the reasons why
gene therapy modalities fail when attempts are made to make the translation from rodent
models to human patients, as the preclinical and clinical treatment strategies vary
dramatically. Therefore, a widely available, reproductive large animal glioma model could
importantly complement studies carried out in rodent models and facilitate translation to
clinical success. It is essential to realize both the strengths and weaknesses of each available
brain tumour model in order to select the most appriopriate option depending on the
character of the study conducted.
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2.3 GENE THERAPY FOR MALIGNANT GLIOMA
Gene therapy is a powerful technique of molecular medicine that allows for a treatment of a
wide array of diseases. The aim of gene therapy is to introduce exogenous genetic
sequences into human patients to correct abnormalities or endow them with novel cellular
functions.
2.3.1 Gene therapy vectors
One of the basic considerations in gene therapy strategies is a choice of delivery method.
Gene transfer vectors may be generally classified as biological and non-biological vectors.
Currently, there is a great selection of delivery methods that should be chosen according to
one’s needs. All of them hold both advantages and drawbacks that will be further
discussed. Furthermore, the new vectors and vector modifications continue to emerge, as
the demand for these vectors rapidly increases.
Figure 3. Vectors  used  in  gene  therapy  clinical  trials  as  of  2011  (modified  from
www.wiley.co.uk/genmed/clinical).
Modified viruses are the most common and efficient gene transfer vectors, as they
possess an innate ability to infect host cells specifically and efficiently. With increasing
developments in molecular virology, a deep insight has been gained into viral structures,
mechanisms of pathogenesis and their life cycles. It makes it possible to modify certain
features  with  respect  to  cell  infection  specificity,  size  of  gene  insert  or  immunogenicity.
Some of the vectors offer genome integration and stable expression, while others allow for
transient gene expression. Commonly used viral vectors for brain cancer gene therapy
clinical trials include adenoviruses (Pedersini, Vattemi & Claudio 2010) and retro- and
lentiviruses (Guo, Che & Li 2011). There are also clinical and pre-clinical trials using some
of the less common viruses such as herpes simplex virus (Manservigi,  Argnani & Marconi
2010), adeno-associated virus (Maguire et al. 2010), baculovirus (Guo et al. 2010), polio
virus (Goetz, Gromeier 2010), Semliki Forest virus (Roche et al. 2010), measles virus (Allen
et al. 2008) and vaccinia virus (Timiryasova et al. 2003). In spite of the availability of the
wide array of viral vectors, several problems still exist such as difficulties in production,
transgene size restrictions, anti-vector immunologic responses and safety issues. Those
concerns lead to increased interest into non-viral systems.
Cellular gene therapy methods are gaining more importance in glioma gene therapy. The
carrier cells such as neural stem cells (Ehtesham et al. 2002a), neural progenitor cells
(Ehtesham et al. 2002b, Arnhold et al. 2003), bone marrow derived stem cells (Lee et al.
2003), or endothelial progenitor cells (Zhang et al. 2010) are used to transfer gene-based
therapeutics to both primary and metastatic brain tumours. Finally, as the field of
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nanotechnology expands, synthetic particles are gaining more and more attention.
However, the effectiveness of current non-biological approaches compare poorly with e.g.
viral vectors, thus limiting their clinical efficacy.
2.3.1.1 Adenoviruses
Adenoviruses are dsDNA nonenveloped, icosahedral viruses with protein shell
encapsulating a nucleoprotein core (Stewart, Fuller & Burnett 1993). Adenoviruses have
been studied since 1950s, resulting in a relatively good understanding of their biology and
possibility for undertaking molecular modifications (Bell et al. 1956).
Figure 4. Simplified cross-section structure of adenoviral capsid (modified from (Alemany et al.
1999)).
Adenoviruses carry a very low risk of mutagenesis, since no clinical or preclinical study
has shown adenoviral DNA integration into the host genome (Stephen et al. 2010). This
feature is a result of the limited duration of gene expression, which usually represents a
hurdle in the therapy of hereditary diseases, but this is not the case in glioma gene therapy,
as its goal is to kill the target cells. Importantly, infection is not dependent on cell cycle
phase,  making  it  possible  to  target  both  dormant  and  cycling  cells  and  even  highly
differentiated cells such as lung, brain, bladder and skeletal muscle cells (Zabner et al. 1997,
Zabner et al. 1997, Bouri et al. 1999, Li et al. 1999). Nevertheless, this wide tropism to
various cell types occurs to be problematic, particularly after intravenous injection. If one
wishes to prevent uncontrolled vector spread, then local delivery is favoured but there is
still an urgent need for vector’s improvement before systemic administration can become a
routine procedure. Another important advantage of adenoviral vectors is the ease of their
large-scale production with high titer stocks. However, it is known that impurities may
cause severe toxic reactions and provoke immune responses, thus the process of production
must be conducted under strict regulations (Hedman et al. 2003).
With respect to safety issues, adenoviruses do not cause life-threatening diseases and
most of them are associated with only mild upper respiratory tract infections (Bell et al.
1956). However, those viruses are strongly immunogenic, creating long-lasting humoral
and cellular immune responses towards the vector as well as transgene and infected cells
(Young, Mautner 2001). Often, this feature is often perceived as a positive side in cancer
gene therapy, since it could potentially activate the immune system to recognise tumour
antigens. Apart from the toxicity considerations, the potential immune response reduces
the effectiveness upon readministration of adenovirus, which has focused research on ways
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to remove neutralising antibodies (Rahman et al. 2001) or reducing the immune response. A
further problem which needs to be resolved is the presence of neutralizing antibodies in the
human population which may result in decreased efficiency of these vectors (Belousova et
al. 2010). Due to their advantages, adenoviral vectors are one of the most commonly used
ones in clinical trials. Nowadays, 24% of all gene therapy clinical trials use adenoviruses for
gene transfer purposes (http://www.wiley.co.uk/genmed/clinical/).
2.3.1.2 Retro- and lentiviruses
Retroviruses belong to a class of broad tropism enveloped viruses containing single
stranded RNA, which is reverse transcribed upon infection and integrated into the host
genome (Sinn, Sauter & McCray 2005). As retroviral vectors have been used widely in basic
research as well as in the clinical trials, they are known to be safe vectors for CNS tumour
gene therapy, providing a long-term expression with low toxicity and immunogenicity to
normal brain tissue (Ram et al. 1993b, Long et al. 1998).
Figure 5. Simplified cross-section structure of wild type lentivirus
(http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/Pages/structure.aspx).
Another aspect of safety features of retroviruses is the fact that they will only transduce
dividing cancer cells and non-dividing normal brain cells will remain unaffected (Miller,
Adam & Miller 1990). Nevertheless, those vectors feature some severe drawbacks. A major
threat comes from their random integration into the genome of the host, raising the
problem of insertional mutagenesis (Uren et al. 2005). The risk of insertional mutagenesis
can be minimised with gene therapy strategies aiming at ultimate cell destruction. Other
disadvantages of retroviruses include the low titers and instability of the viral particles
(Roth et al. 1996, Tait et al. 1997). Finally, although retroviruses were eagerly used during
the early gene therapy trials, their applications nowadays have been greatly reduced due to
their low transduction efficacy. The reason for retroviral inefficiency is that they are able to
transduce  only  dividing  tumour  cells  and  there  is  a  low  mitotic  rate  of  tumour  cells  in  a
given treatment window. In an attempt to increase vector concentration and transduction
rates retrovirus viral packaging cells (VPCs) were created, but nonetheless the transduction
efficacy is still considered to be low even with those systems (Rainov 2000).
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Table 2. Comparison  of  viral  vectors  commonly  used  in  gene  therapy  of  GBM  (based  on
(Rissanen, Yla-Herttuala 2007, Hillgenberg, Tonnies & Strauss 2001, Roemer, Johnson &
Friedmann 1992, Asadi-Moghaddam, Chiocca 2009)).
Vector Genomic integration Expression Advantages Disadvantages
Adenovirus Episomal Transient High transduction
efficacy
High transgene
capacity
Wide tropism
Ease of production
in high titers
Quiescent cells
transduction
Transient expression
Inflammatory reactions
Lentivirus Integrating Long term High transgene
capacity
Quiescent cells
transduction
Low immune
response
Non-specific integration
Safety
High titers difficult to
produce
AAV Episomal with low
frequency of genomic
integration
Long term Quiescent cells
transduction
Moderate immune
response
Serotype specific
tropism
Limited transgene
capacity
Large quantities difficult
to produce
HSV Episomal with low
frequency of genomic
integration
Transient Very high transgene
capacity
Transient expression
Immunogenicity and
toxicity
Potential reactivation
and recombination with
wild type HSV
Lentiviruses  are  a  subfamily  of  retroviruses  that  combine  both  the  ability  to  stably
integrate into the genome and transduce non-dividing cells. In order to prevent the
formation of replication competent viruses, lentiviral vectors have been extensively
modified (Sinn, Sauter & McCray 2005), yet questions about their safety have been raised
when it comes to clinical trials. Currently, they are commonly utilized in basic research,
particularly in experiments aimed at understanding the molecular basics of gliomagenesis
and creating novel animal models.
Like all retroviral vectors, lentiviruses offer the potential for stable single-copy gene
insertion into a host cell chromosome and targeted gene transfer into cells bearing an
appropriate viral receptor. The major reason for considering lentiviruses in preference to
other retroviruses is their ability to target cells that are in the G0 phase of the cell cycle, thus
making even quiescent tumour cells vulnerable to gene therapy (Sinn, Sauter & McCray
2005). Lentiviral vectors have been successfully used for glioma therapy in experimental
models and are able to cause complete remission of solid tumours (Huszthy et al. 2009).
One of the major disadvantages of lentiviruses is that the current production strategies
result in a relatively low titre of vector.
2.3.1.3 Cell based therapy
Recently,  gene  delivery  by  embryonic  stem  cells  has  gained  much  interest.  Stem  cell
therapy may be an answer to poor delivery efficiency of other vectors as it has been shown
that the cells present migratory tropism for malignant cells. This interesting phenomenon
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could be due to guidance signals emitted by angiogenic-activated microvasculature
(Schmidt et al. 2005). One exciting study conducted by Li and co-workers showed that
neural stem cells transduced with the herpes simplex thymidine kinase gene, were able to
migrate  towards  malignant  cells  even  when  implanted  in  the  contralateral  hemisphere  of
C6 rats. Moreover, upon ganciclovir administration, growth of the tumour decreased and
survival was significantly prolonged, suggesting that neural stem cell (NSC) therapy might
be used for targeting infiltrative glioblastomas (Li et al. 2007). Not only are NSCs able to
target  GBM,  it  has  been  shown  that  after  tail  vein  injecton  they  do  not  only  home  in  on
intracranial tumours, but also subcutaneous tumours of both neural and non-neural origin
(Brown et al. 2003). Nevertheless, before NSC therapy can be widely used, some important
issues concerning their possible side effects must be resolved. For example, their potential
ability for neoplastic transformation needs to be carefully assessed. Interestingly, it has
been  shown  that  glial  progenitor  cells  are  able  to  give  rise  to  gliomas  not  only  when
expressing mitogenic protein, but also when they simply in the vicinity of those cells
(Assanah et al. 2006), which may risk that they could contribute to the progression of the
disease instead of its elimination.  The resolution of this problem may lie in the discovery
that embryonic stem cells can be differentiated into astrocytes prior to intracerebral
delivery and yet maintain their migratory properties (Uzzaman et al. 2005). It has been
shown that embryonic stem cell-derived astrocytes can be genetically engineered to deliver
therapeutic genes in vivo (Uzzaman, Keller & Germano 2009). Nevertheless, further
research into the biology of stem cells will be needed before one can evaluate their potential
as novel, clinically useful gene vectors.
2.3.1.4 Synthetic vectors
Synthetic vectors include DNA or RNA molecules that are delivered into a cell with the use
of nanoparticles. Synthetic vectors have attracted interest as there is a growing pressure for
development of safe gene delivery methods. The major advantage of nanoparticles is the
ease of their use and production as well as reduced immunogenicity in comparison to viral
vectors. However, the poor efficiency of gene delivery has restricted their applications.
Liposomes  have  been  the  most  extensively  studied  non-viral  vectors.  Since  DNA  is
negatively charged, it is relatively easy to conjugate it to positively charged lipids. The
cationic  lipids  are  then  assembled  into  a  liposome,  a  bilayer  vesicular  structure  with  the
negatively charged DNA aggregates clustered between many liposomal particles
(Sternberg, Sorgi & Huang 1994). Liposomes have already been used in clinical trials in the
therapy of brain tumours (Yoshida et al. 2004, Wakabayashi et al. 2008, Voges et al. 2003).
They  are  perceived  as  one  of  the  more  promising  gene  vectors  particularly  for  RNAi
delivery (de Fougerolles 2008). Unfortunately, their stability is readily disturbed by many
physical and chemical factors and by now the efficiency of transfection is significantly
lower than with viral vectors, thus novel approaches are tested to improve nanoparticles.
For example one of the successful methods to enhance the liposome targeting into glioma
cells is to spike them with monoclonal antibodies (Zhang et al. 2004). Nevertheless,
considerable effort will be still necessary to develop novel means to enhance the delivery of
synthetic vectors.
2.3.2 Gene therapy strategies for glioblastoma multiforme
Gene therapy for cancer is one of the main applications of gene therapy and numerous
strategies have been employed to combat glioma. The most common approaches include
suicide (pro-drug activation) gene therapy, anti-angiogenic gene therapy and oncolytic
virotherapy. Another interesting approach aims at boosting the immune response against
malignant cells. Last, but not least, gene therapy may target tumour suppressor genes and
cell-cycle modulators, however since glioblastomas are very heterogenous tumours, it has
become clear that the therapy should affect the broad spectrum of the disease or even
consist of multi-modality treatment strategies, rather than focusing on a single mutation.
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Despite the wide array of available treatment methods, few of the trials have advanced
from basic research to phase III clinical trials (Iwami, Natsume & Wakabayashi 2010, Wirth
et al. 2009, Maatta et al. 2009). However, with further progress in vector development and
targeting methods, one must hope that in the near future the progress made in basic
research will be translated into clinical success.
2.3.2.1 Suicide gene therapy
Suicide gene therapy modifies the cancer cells to sensitize them to a chemotherapeutic
agent that is otherwise non-toxic. Essentially, a gene coding for an enzyme converting a
non-toxic prodrug into a poisonous agent is inserted into the recipient cells. Subsequent
administration of the prodrug causes the death of the target cells. In comparison to
conventional  chemotherapy  agents,  prodrugs  do  not  have  any  intrinsic  activity  in
unmodified cells. Moreover, a high local tumour drug concentration can be obtained, since
the change to the cytotoxic metabolite occurs only within the transduced tumour
microenvironment, resulting in minimal systemic toxicity. The two critical properties of
suicide genes are to be absent or minimally expressed in humans and to be harmless. Most
popular suicide genes in use are in fact bacterial, fungal or viral enzymes (Portsmouth,
Hlavaty & Renner 2007). The gene encoding HSV-1 thymidine kinase (HSV-tk) was the first
and has been the most extensively studied suicide gene.
HSV-tk was the first reported gene therapy strategy employing a suicide gene (Moolten
1986). Following HSV-tk gene transfer, the cells are exposed to ganciclovir (GCV), which
becomes phosphorylated by the viral enzyme to monophosphate and then further on to
triphosphate, this time by normal cellular kinases. The phosphorylated ganciclovir, is
readily incorporated into replicating DNA strands, resulting in termination of DNA
synthesis and cell death (Cheng et al. 1983). Since HSV-tk is approximately 1000 times more
efficient than its cellular counterpart,  it  is virtually toxic only to dividing cells (Elion et al.
1977). Ganciclovir triphosphate is highly charged and thus insoluble in lipid membranes,
yet  it  was  found that  not  only  the  cells  carrying HSV-tk  were  affected by the  cytotoxicity,
but  surrounding cells  as  well.  This  phenomenon was called the  bystander  effect  (Moolten
1986).  Mesnil and coworkers have proven that the bystander effect is primarily caused by
the transfer of cycotoxic agents through gap junctional intercellular communication that is
mediated by a group of proteins called connexins (Mesnil et al. 1996). A wide range of
sensitivity to this effect among various cell types has been reported (Touraine 1998), which
may in part be caused by diversity in the abundance of gap junctions.
Interestingly, cells with low gap junction intercellular communication can exhibit good
bystander cytotoxicity (Boucher, Ruch & Shewach 1998), which indicates that there must be
other factors influencing the bystander effect.  It  is possible that there is some contribution
from apoptotic vesicles, containing phosphorylated ganciclovir, that are released from
dying cells, and these were found to be phagocytosed by neighbouring cells (Freeman et al.
1993). The host immune system also plays a profound role in mediating the bystander effect.
It  is  known that  the  intact  immune system is  required for  a  significant  bystander  effect in
vivo and nude mice do not exhibit any regression of subcutaneous tumours even when
composed of 50% of HSV-tk positive cells (Ramesh et al. 1996). Moreover, it can stimulate
the development of systemic antitumour immunity following treatment with suicide gene
therapy. For example, those animals that underwent HSV-tk/GCV treatment were
protected against rechallenge with melanoma (Vile et al. 1994). Interestingly, there are also
reports of the so-called distant bystander effect, where local suicide gene therapy is able to
cause regression of distant metastasis, like in the case of Misawa and coworkers, who
reported regression of liver metastasis after eradication of HSV-tk positive intraperitoneal
tumour (Misawa et al. 1997).
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Figure 6. HSV-tk suicide gene therapy. After the delivery of HSV-tk into the target tumour cell,
the newly expressed enzyme, thymidine kinase phosphorylates ganciclovir to produce
ganciclovir monophosphate (GCV-P). GCV-P can be further transported to adjacent cells to
cause a bystander effect. Mammalian kinases can add two additional phosphates to form
ganciclovir  triphosphate  (GCV-P-P-P),  which  can  be  incorporated  into  DNA.  Nonetheless,  DNA
polymerases are unable to replicate DNA containing GCV-P-P-P, which provokes interruption of
mitosis followed by cell death (modified from (Hurwitz et al. 2003)).
HSV-tk/GCV suicide gene therapy has been evaluated in many cancer types (Portsmouth,
Hlavaty & Renner 2007), however it is particularly favorable in brain cancer therapy, as
primarily it is cancerous cells that undergo division which are affected in contrast to the
mostly non-dividing normal brain cells.
2.3.2.2 Anti-angiogenic gene therapy
Tumourigenesis is a complex, multistep process that involves changes in tumour as well as
the stromal microenvironment including the vasculature. As the tumour growth progresses,
it  needs  to  match the  new metabolic  demands to  sustain  further  growth.  It  is  well  known
that one of the rate limiting steps for tumour progression is gaining access to the host
vascular  system and further  generation of  its  own blood supply and it  is  believed that  no
tumour will grow beyond 2-3 mm3 in size without angiogenesis (Lawler, Peruzzi & Chiocca
2006). Given the importance of angiogenesis for tumour growth and progression, it has
been postulated that the inhibition of this pathogenic process could be used to combat brain
tumours.
Neovascularisation in glioblastomas is thought to be driven primarily by VEGF
signalling (Plate et al. 1992). Angiogenesis induced largely by VEGF-A leads to immature,
dysfunctional  vessels  with  an  impaired  blood-brain  barrier  and  prominent  vasogenic
oedema. The VEGF-A receptor, VEGFR2, is the main mediator of its physiological effects on
endothelial cells i.e. survival, proliferation, migration and permeability (Dvorak 2002). High
levels of VEGF-A expression alone are known to initiate angiogenesis in quiescent
vasculature, which is thought to prove the importance of angiogenic factors in gliomas
(Pettersson et al. 2000) thus making it a primary target for anti-angiogenic gene therapy.
Anti-angiogenic therapy also helps to normalise the blood flow, facilitating also the
adequate delivery of conventional therapeutics. Additionally, normalised vasculature
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diminishes access of tumour cells to vascular system, decreasing the risk of metastasis.
Finally, it has been suggested that the abnormal vessels in gliomas may create a vascular
niche suitable for glioma stem cells (Gilbertson, Rich 2007). Therefore, their destruction
would have a positive effect on reduction of recurrences.
2.3.2.3 Virotherapy
Replication-competent oncolytic viruses hold great promise for future therapies of gliomas.
Viral  oncolysis  involves  the  use  of  viruses  to  provoke  host  cell  killing via viral
multiplication and further spread to neighbouring cells at the same time sparing healthy
cells.  Several  features  of  wild  type  adenoviruses  can  be  tailored  to  acquire  tumour
replication properties. For example, deletion of viral genes that interact with tumour
suppressor genes,  modification of tropism to infect malignant cells with more potency as
well as the inclusion of elements of transcription in the viral genome that are sensitive to
transcription factors upregulated in cancer cells (Jiang et al. 2009). For example, Onyx-015
utilizes deletion of E1B-55k. This adenoviral protein binds to and inactivates p53 in order to
prevent apoptosis and thus facilitate the spread of the virus to neighbouring cells. Once this
region is deleted, adenoviruses are unable to replicate in the cells expressing p53.
Nonetheless, because of common p53 mutation/depletion in malignant cells, the replication
phenotype is fully acquired resulting in cancer cell lysis (Jiang et al. 2009). An interesting
experiment  conducted  by  Jiang  et  al  has  shed  light  on  another  interesting  property  of
oncolytic adenoviruses, this time those targeting retinoblastoma pathway (Jiang et al. 2007).
They were able to show that adenovirus-based therapy may be an effective strategy to
target and eliminate brain tumour stem cells, which is crucial given their self-renewal
properties. Furthermore, the in vivo experiment achieved a significant survival prolongation
in the animals. Similarly to adenoviruses, HSV-1 might also be modified to exploit their
abilities for cytolysis.
2.3.2.4 Genetic immune modulation
The principle concept behind immune modulation is to enhance the immune responce
against tumours via cytokine expression. Several cytokines such as IL-2 (Gansbacher et al.
1990b, Sobol et al. 1995a), IL-4 (Yu et al. 1993), IL-12 (Parker et al. 2000), IFN- (Qin et al.
1998), IFN- (Gansbacher et al. 1990a) and GM-CSF (Herrlinger et al. 1997) are frequently
used as immune modulators, either being introduced directly into tumour or used as
enhancers in vaccination therapy. However, some of those cytokines such as IL-2 and IFN-
may cause severe CNS toxicity (Tjuvajev et al. 1995). IFN- has also been considered as an
interesting option for glioma treatment as it is able to inhibit cell cycle progression, induce
apoptosis and increase the expression of MHC-1 molecules (Yang et al. 2004). The lack of
dendritic  cells  (DCs)  in  the  brain  parenchyma  has  been  a  major  concern  about  the  use  of
immunotherapy in glioma (King et al. 2005). An attractive approach was based on the
ability to boost immune response by recruiting antigen-presenting cells (dendritic cells and
macrophages) introducing the fms-like tyrosine kinase-3 ligand transgene. After its
introduction together with HSV-tk, ~70% of rats displaying a large intracranial GBM were
rescued (Ali et al. 2005). Interestingly, this combined therapy inhibited the progression of a
second glioblastoma multiforme implanted in the contralateral hemisphere at the same
time as the primary treated tumour in a rat model of multifocal glioblastoma multiforme
(King et al. 2008).
2.4 LIPOXYGENASES
Lipoxygenases (LOs) are a family of nonheme iron dioxygenases that recognize the 1,4-
pentadiene structure of polyunsaturated fatty acids and incorporate single oxygen
molecules into their substrate fatty acids at specific carbon atoms. Mammalian
lipoxygenases are divided into 5, 8, 12 and 15 lipoxygenases, according to their carbon
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number specifically at which they predominantly oxygenate arachidonic acid (Brash 1999).
However,  this  classification  was  found  to  be  too  simple  and  a  new  one,  based  on
phylogenic relatedness has been advised. Thus, the enzymes are grouped into four clusters:
12(S)/15(S)-LOs (reticulocyte and leukocyte types), platelet-type 12(S)-LOs as well as 5(S)-
LOs and epidermis-type LOs (Furstenberger, Marks & Krieg 2002).
Arachidonic acid is a secondary messenger and in response to various external stimuli, it
is released from cell membrane and further metabolised either by cyclooxygenase or
lipoxygenase pathways. Together with linoleic acid it is peroxidated by lipoxygenases
primarily to hydro-peroxyeicosatetraenoic acid (HPETE) and hydroperoxyoctadecadienoic
acid (HPODE) respectively. Those are further reduced to hydroxyeicosatetraenoic (HETE)
and hydroxyoctadecadienoic (HODE) acids (Furstenberger et al. 2006). Products of
lipoxygenases may act either as the ultimate signalling molecules or as intermediates that
are further transformed into secondary products. Biological effects of LO derived products
are mediated either through G protein-coupled cell surface receptors or in an intracrine
manner by activating nuclear receptors like peroxisome proliferator activated receptors
(PPARs). Lipoxygenases are able to modify membrane structures and initiate secondary
oxygenations through peroxidation reactions (Furstenberger et al. 2006). As oxidised
metabolites are able to alter the redox balance within the cells, they mediate signal
transduction and regulate various gene expression pathways that regulate cell growth, cell
survival, angiogenesis and immunomodulation just to name a few.
2.4.1 15-lipoxygenase-1
15-LO-1 is a multifunctional enzyme able to produce a vast number of metabolites with
diverse bioactivities. It catalyzes the transformation of free arachidonic acid into 12-HPETE
and 15-HPETE, which are subsequently reduced to their hydroxyl derivatives (12-HETE
and 15-HETE) in the ratio 1:12 (Kuhn et al. 1993). Interestingly, the mouse homologous
enzyme, 12-LO, produces more 12-HETE than 15-HETE, namely in the ratio of 3:1 (Chen et
al. 1994). In addition to arachidonic acid metabolism, 15-LO-1 also takes part in the
transformation of linoleic acid to 13-hydroxyoctadecadienoic acid (13-HODE) (Haas et al.
1988). Once the reducing capacity of a cell is impaired, 15-LO-1 displays other catalytic
properties. It is known to possess a hydroperoxidase activity that produces radical
intermediates after fatty acid decomposition. However, it must be stated that this reaction
per se is not an efficient source of free radicals, as they tend to remain enzyme bound and
undergo further reactions with aldehydes, ketodiens and alkanes (Noguchi et al. 2002).
To complicate matters further, 15-LO-1 has a leukotriene and lipoxin synthase activity
that produces a number of bioactive molecules that are able to interact with diverse cellular
pathways often in opposing manners (Bryant et al. 1985, Kuhn et al. 1987). Additionally, in
contrast to the other members of lipoxygenase family, 15-LO-1 is characterised by low
substrate specificity. It is able to introduce molecular oxygen to polyunsaturated fatty acids
not only in the free form, but also into more complex compounds such as cholesterol esters,
plasma lipoproteins and phospholipids (Furstenberger et al. 2006). Moreover, there are
substantial species-specific differences in the catalysis pathways and their regulation which
contribute to the poor understanding of the molecule. Humans express reticulocyte-type
15-LO-1, mice an orthologous leukocyte-type 12-LO, while rabbits express both types
(Kuhn, Thiele 1999). Accordingly, animal models vary with iso-enzymes and thus, produce
different amounts of metabolites, which at least in part may contribute to conflicting results
on 15-LO-1 properties. 15-LO-1 is involved in elaborate manner in many pathological
conditions, such as inflammatory processes, atherogenesis and cancer.
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Figure 7. 15-lipoxygenase lipid substrates and products. Upon arachidonic acid metabolism, 15-
LO-1  generates  lipid  hydroperoxides  (HPETEs)  as  the  primary  product.  The  latter  are  rapidly
reduced intracellularly to their corresponding hydroxides (HETEs). Those hydroperoxides can
serve as precursors for the generation of other classes of secondary lipid mediators.
Interestingly, upon arachidonic acid metabolism, 15-LO-1 produces 90% 15-HPETEs and 10%
12-HPETES. 15-LO-1 is able to metabolize linoleic acid as well, generating
hydroperoxyoctadecadienoic  acid  (13-HPODE)  which  is  further  peroxidized  to  13-HODE.
Docosahexanoic  acid  is  another  possible  substrate  for  15-LO-1  which  metabolizes  the    3
fatty acid to a hydroperoxy derivative which is rapidly transformed into two epoxy intermediates
(modified from (Dobrian et al. 2011)).
2.4.1.1 15-lipoxygenase-1 in tumourigenesis
The levels of 15-LO-1 expression have been described in a variety of normal and cancer
tissues. Notably, it is expressed in healthy tissues and benign lesions, but its level is
significantly reduced for example in breast, bladder, colon, skin and lung carcinomas
(Furstenberger et al. 2006). Such loss of expression during tumourigenesis may suggest that
15-LO-1 has cancer inhibiting properties. Many conflicting results have been obtained from
prostate cancer studies, whereas 15-LO-1 expression results in opposing effects, namely it
leads to an increased rate of tumourigenesis (Kelavkar et al. 2001).
Studies  analyzing  the  biological  relevance  of  15-LO-1  in  cancer  progression  are
inconsistent as the enzyme is known to exhibit differential effects in various cancer cell
types. The reasons may be caused by diverse metabolite production and depend on the
type of the metabolite produced or their ratio in the tissues. Considering the complexity of
tumourigenic  process,  the  elucidation  of  the  precise  mechanism of 15-LO-1 activities is
challenging,  nonetheless,  it  is  important  to  design  new  therapeutic  strategies  for
modulating cell proliferation and cancer progression. Undoubtedly, further studies are
needed to resolve unanswered questions regarding the role of 15-LO-1 in various cancers.
2.4.1.2 15-lipoxygenase-1 in apoptosis
Sandstrom and co-workers proved that the addition of 15-HETE and 13-HODE induces
apoptosis (Sandstrom et al. 1995). Up-regulation of 15-LO-1 is known to induce apoptosis
and inhibit colon cancer growth (Nixon et al. 2004, Shureiqi et al. 1999) as well as xenograft
growth in nude mice (Nixon et al. 2004). Several publications have examined this property
of 15-LO-1 metabolites, particularly 13-HODE. The research on colon cancer revealed that
13-HODE may act through PPAR- to reverse the malignant changes (Sarraf et al. 1998).
Similar pro-apoptotic properties were reported for other gastrointestinal tract malignancies
such as esophageal, gastric and oral cavity cancer cells (Kim et al. 2006, Sasaki et al. 2006,
Wu et al. 2003, Shureiqi et al. 2001). Last, but not least, 15-LO-1 could be an important
player in apoptosis of malignant glioma cells. GBM tumours are known to express high
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levels of IL-13R2 receptor, which in spite of binding IL-13 with extremely high affinity,
acts as a decoy and does not mediate signal transduction. Hsi and coworkers showed that
the inhibition of this receptor with siRNA, restores the normal endogenous IL-13 signalling
cascades that involve 15-LO-1 mediated apoptosis. As the IL-13 decoy receptor is inhibited,
15-LO-1 is induced, which in turn generates 13-HODE, leading to the activation of PPAR
and apoptosis (Hsi et al. 2011).
Other PPARs have also been linked to pro-apoptotic properties of 15-LO-1. 13-HODE is
known to  bind to  PPAR- and down-regulate  its  protein  expression.  It  was  shown in vivo
that nonsteroidal anti-inflammatory drugs (NSAID) could reduce the tumour growth and
down-regulate PPAR-, but this effect was prevented once 15-LO-1 expression was blocked
(Shureiqi et al. 2003). It is possible that the apoptosis of tumour cells may be caused as well
by the interplay with PPAR receptors as it  was shown in colon cancer cells that 13-HODE
can mediate the activation of PPAR- by down-regulating PPARs  and , ultimatelly
resulting in the induction of apoptosis (Zuo et al. 2006). In addition, 15-HETE, another 15-
LO-1 metabolite, was reported to depress cell proliferation (Yu et al. 2004). The mechanisms
of action might be similar to already explained activity of 13-HODE, as Shappell and
colleagues described 15-HETE mediated proliferation inhibition in prostate carcinoma cells
through activation of PPAR- (Shappell et al. 2001). Additionally, both, 15-HETE and 13-
HODE are known to diminish expression of matrix metalloproteinase-9 by acting through
PPAR- and PPAR- (Shu et al. 2000, Marx et al. 1998). It is of particular importance as
matrix metalloproteinases are involved in tumour progression and metastasis.
15-LO-1 is also able to induce apoptosis through other mechanisms. Histone deacetylases
(HDAC) are epigenetic regulators of gene expression and have recently emerged as
potential  cancer  therapeutics.  It  has  been  shown  that  HDAC  inhibitors  are  able  to  induce
15-LO-1 expression(Kelavkar et al. 2000), which correlates with 13-S-HODE expression,
resulting in growth inhibition and apoptosis (Hsi et al. 2004). As in case of NSAIDs and
HDAC inhibitors, the methyltransferase inhibitors are also able to induce 15-LO-1
expression in colorectal cancer cells, resulting in an increase in 13-S-HODE production and
further growth cessation and apoptosis (Hsi et al. 2005).
Nevertheless, the role of 15-LO-1 in the cell cycle and apoptosis is not straightforward.
There are numerous publications shedding light on the pro-tumourigenic actions of this
multifaceted enzyme. Those reports, however, have mainly focused on prostate cancer cells
and models. Kelavkar and colleagues reported that the intensity of 15-LO-1 staining
correlated with the degree of malignancy (Kelavkar et al. 2000) and its overexpression led
to an increased rate of tumourigenesis (Kelavkar et al. 2001). Those results were confirmed
by two independent in vivo studies in mice, where adenoviral driven 15-LO-1 expression
induced neoplastic lesions (Sen et al. 2006, Kelavkar et al. 2006). In the prostate cancer cells,
unlike the situation in colon cancer, 13-HODE was shown to possess mitogenic properties
by evoking an increase in the expression of insulin-like growth factor-1(Kelavkar, Cohen
2004). Furthermore, in contrast to previously discussed data, the treatment with a DNA
methyltransferase inhibitor and HDAC inhibitor reduced 15-LO-1 expression in prostate
cancer cells (Kelavkar et al. 2007). The case of reverse expression levels of 15-LO-1 in
prostate cancer as well as opposing results of its effects in tumour progression are further
evidence that lipoxygenases may act diversely, depending on the tumour origin. It  is thus
crucial to critically examine their role as a cancer therapeutic for each particular type of
tumour.
2.4.1.3 15-lipoxygenase-1 in angiogenesis
With the recent progress in understanding the biology of 15-LO-1, has come greater
awarenes of its possible roles in tumour neovascularization. Though there are few reports
about its potential role in angiogenesis, currently there is increasing evidence that 15-LO-1
and its metabolites may be important players in the process of tumour vasculature
formation and remodelling.
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The first insight into the potential role of 15-LO-1 in tumour angiogenesis was made by
Harats and co-workers conducting research on mammary gland and Lewis lung carcinoma.
These researchers showed that the transgenic mice overexpressing 15-LO-1 were
characterised with reduced angiogenesis and tumour growth, in conjunction with the
increased ratio of apoptosis (Harats et al. 2005). Recently, it was demonstrated that the co-
administration of 15-LO-1 together with pro-angiogenic molecules such as VEGF-A and
PlGF significantly decreased their effects, influencing vasodilatation, vascular permeability
and capillary perfusion (Viita et al. 2008). Moreover, further investigations revealed that 15-
LO-1 was able to prevent VEGF-A induced neovascularisation in rabbit eyes by reducing
VEGF-A as  well  as  VEGFR2 expression,  and thus  could be  considered as  a  potential  new
anti-angiogenic treatment strategy (Viita et al. 2009).
Viita has provided evidence for the anti-angiogenic properties of 15-LO-1 and proposed
three plausible mechanisms to explain her findings. The data suggests that 15-LO-1 can
suppress the expression of VEGF-A and PlGF already at the mRNA level. The action is
sufficiently  powerful  to  oppose  all  the  angiogenic  effects  previously  induced  by  VEGF-A
and PlGF, although the mechanism of action is not fully understood, though destabilisation
of transcripts seems probable. Secondarily, Viita has demonstrated that 15-LO-1 can block
VEGF-induced angiogenesis and vascular permeability by reducing eNOS expression,
resulting in a reduced amount of bioactive free nitric oxide (NO). Interestingly, NO can
promote tumour progression not only via its pro-angiogenic properties, but it is also
associated with inflammation and metastasis (Fukumura, Kashiwagi & Jain 2006). Thus, at
least  in  theory,  modulation  of  NO  levels  by  15-LO-1  might  be  mediating  the  anti-
tumourigenic actions at various levels. Finally, as was previously discussed, 15-LO-1 can
generate endogenous ligands for PPAR-, thus a connection between 15-LO-1 metabolites
and PPAR- directed angiogenesis has been proposed. It is known that PPAR- binding to
VEGFR2  promoter  induces  VEGFR2  expression,  but  once  a  ligand  binds  to  PPAR- this
causes inhibition of VEGFR2 expression (Xin et al. 1999). Accordingly, the proposed
mechanism is that 13-S-HODE could act as a ligand for PPAR- and prevent VEGF-induced
VEGFR2 expression.
Contrasting results have been reported for other 15-LO-1 metabolites. Although the
enzyme preferentially converts linoleic acid to 13-S-HODE, it can also metabolise
arachidonic acid to 15-S-HETE and to a lesser extent to 12-S-HETE. It has been
demonstrated that hypoxia could induce the expression of 15-LO-1, leading to the
production of 15-S-HETE and 12-S-HETE metabolites, which stimulated the angiogenic
differentiation of human retinal microvascular endothelial cells (Bajpai et al. 2007). It is also
known that 15-S-HETE is an important mediator in the pathogenesis of vascular lesions and
has the ability to induce angiogenesis (Kundumani-Sridharan et al. 2010). Similarly, 12-S-
HETE has been described as a potential pro-angiogenic factor. Evidence for this proposal
came from a prostate cancer study, where the introduction of 12-LO transfected PC3 cells
producing 12-S-HETE in vivo,  resulted  in  increased  tumour  growth  and  enhanced
angiogenesis (Nie et al. 1998).
2.5 GENE THERAPY CLINICAL TRIALS FOR GLIOBLASTOMA
MULTIFORME
Gene therapy has become a promising treatment modality for highly malignant tumours
such as GBM. The most frequently used therapeutic strategies in clinical trials include
suicide gene therapy, immunotherapy as well as use of oncolytic vectors.
2.5.1 Suicide gene therapy
In the early 90’s, numerous studies confirmed that tumour regression as well as increased
survival could be achieved by implanting HSV-tk producing fibroblasts in rodent models of
glioma (Culver et al. 1992, Rainov et al. 1996, Ram et al. 1993a). The first clinical trials that
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used HSV-tk therapeutic gene utilized VPCs, revealing that the treatments were safe, but
not efficient, probably due to poor transduction of the tumour cells (Valery et al. 2002,
Packer et al. 2000). The inefficiency of VPCs was confirmed in a phase III trial involving 248
patients, where VPC mediated gene therapy failed to confer any survival benefit and was
associated with an increased rate of side effects (Rainov 2000). The study of Puumalainen
performed on a small group of patients demonstrated the superiority of adenoviral vectors
over the commonly used VPCs (Puumalainen et al. 1998). Transduction efficiency with an
adenoviral vector was significantly higher (5.7-11.3%) than could be achieved with a
retroviral vector (0.01 - 4.0%) and it also produced the treatment response, which was not
detected in other patients. This study indicated that it might be preferable to use adenoviral
vectors for glioma suicide gene therapy.
In 2000 Trask et al published data from a phase I clinical trial where 13 patients with
recurrent malignant tumours were given a single intratumoural injection of adenovirus
bearing HSV-tk in four different doses to determine the safety of the treatment (Trask et al.
2000). The patients who received the highest dose of the vector experienced CNS toxicity,
injection-site hematoma, edema, seizures and hydrocephalus. The study established a
safety dose of up to 2x1011 VPs which has been followed subsequently by other researchers
(Maatta et al. 2009). However, in contrast to the Trask study, multiple injections have been
preferred for treatment protocols in an attempt to reach numerous sites and to facilitate the
virus spread in the whole cavity (Immonen et al. 2004, Smitt et al. 2003, Germano et al.
2003). In a phase IIa trial, the efficiency of adenoviral gene transfer and VPCs was again
compared, in favour of the virus. The mean survival of patients treated with AdHSV-tk was
15 months, while it was a mere 8.3 months in the control group and 7.4 months in the VPC
group (Sandmair et al. 2000). The study has provided the first evidence for the efficacy of
adenoviral vectors over VPCs in the suicide therapy of malignant gliomas as well as
demonstrating the clinical safety of both adenovirus and retrovirus vectors. The phase IIb
study on sitimagene ceradenovec was the first randomized, controlled study, which
demonstrated an increased survival of patients treated with AdHSV-tk-based therapy. A
group of 17 patients was administered gene therapy by local injections into the tumour bed,
followed by GCV for 14 days. Control patients (n=19) received the standard treatment of
surgical debulking combined with radiotherapy. The mean survival of HSV-tk treated
patients was significantly longer (70.6 +- 52.9 weeks compared to 39.0 weeks)(Immonen et
al. 2004). As the IIb clinical trial results were encouraging, a phase III trial was initiated and
the preliminary results were released in 2008. The patients treated with sitimagene
ceradenovec plus temozolomide demonstrated a significant improvement in median
survival when compared to standard care. The study has again confirmed the safety of
gene therapy as the adverse effects reported were in accordance with those previously
described (van Putten et al. 2010).
Apart from exerting a direct cytotoxic effect, the suicide gene therapy may act in another
way. It is known that HSV-tk is able to transduce and destroy dividing endothelial cells
(Puumalainen et al. 1998), thus it could be also responsible for an additional anti-angiogenic
effect (Lawler, Peruzzi & Chiocca 2006). Finally HSV-tk/GCV therapy was shown to be
effective as an adjuvant therapy as it was proven that it could sensitize gliomas to chemo-
and radiotherapy (Nestler et al. 2004, Valerie et al. 2000, Rainov et al. 2001).
2.5.2 Oncolytic virus therapy
Onyx-015 was the first oncolytic vector that was tested under clinical settings. The
application of Onyx-015 to brain tumour patients demonstrated that the oncolytic virus was
safe, but it did not achieve any significant anti-tumour activity (Chiocca et al. 2004).
Nevertheless, the use of Onyx-015 as an adjuvant has been thoroughly investigated. The
most studied oncolytic HSV vector is G207. In a phase Ib clinical trial, it was used to treat
six patients with resectable, recurrent GBM. The patients were given two administrations of
the virus via a direct injection into the tumour mass, followed by surgical resection several
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days later. The second dose was administered as multiple injections into the tumour post
resection cavity (Markert et al. 2009). The high safety profile of the vector was confirmed,
and even though this study was not designed to demonstrate therapeutic efficacy, viral
replication was observed and limited evidence of anti-tumour activity was reported.
Further clinical trials using this vector are being planned.
2.5.3 Immunotherapy
In recent years, it has become apparent that the direction of clinical trials is slowly shifting
towards immune gene therapy. There are several clinical trials for GBM focusing on
cytokine gene therapy, as the advantages of in situ secretion over systemic administration
i.e. lower toxicity, high local concentrations and longer cytokine persistence are evident.
The tumour cells are now being transduced with cytokines such as IL-2 (Sobol et al. 1995),
IL-12 (Ren et al. 2003) and IFN- (Yagi et al. 1994). For instance several early phase clinical
trials for IFN- provided interesting insights into the possibilities of using this strategy for
GBM treatment. IFN- is a cytokine with direct anti-proliferative and immunomodulating
effects (Yagi et al. 1994). A small clinical phase I trial consisting of 5 patients, has proved the
concept of using this approach (Yoshida et al. 2004). At 10 weeks after the start of treatment,
2 patients showed more than 50% reduction in tumour size, while others had stable disease.
The median survival was longer for the treated patients when compared to historical
controls. Further histological investigation revealed profound changes in histology and
gene expression related to the immune response, apoptosis and neovascularisation
(Wakabayashi et al. 2008).
Numerous preclinical studies have reported strong immune responses to the tumour
upon vaccination. Initial vaccination strategies involved subcutaneous inoculation of
irradiated autologous tumour cells. The first GBM patient treated with this approach
received subcutaneous injections of a mixture of irradiated autologous tumour cells with
genetically modified fibroblasts that secreted IL-2 (Sobol et al. 1995). Since the treatment
resulted in marked tumour necrosis and increased cytotoxic T cell-mediated antitumour
immunity, other similar vaccination studies soon followed (Holladay et al. 1996, Wood et al.
2000). Despite the promising results in autologous tumour cell vaccinations, a novel
approach based on dendritic cells was introduced to induce more efficient and specific
response. Dendritic cells (DCs) are the most potent antigen-presenting cells in the immune
system and thus have been widely studied as vaccine vehicles. DCs are obtained from
peripheral blood stem cells and further either pulsed with peptides eluted from tumour
cells or with tumour cell lysates. The vaccination with DCs pulsed with autologous tumour
peptides has been shown to be safe and to elicit peripheral tumour-reactive cytotoxic T cell
activity. The number of tumour responses was low, nevertheless the combination of this
treatment strategy with chemotherapy, achieved a significantly prolonged progression-free
and overall survival (Wheeler et al. 2004). Preparation of DCs stimulated with tumour
lysates is faster and much less laborious than the previous immune-based techniques. Trials
using  this  approach  proved  the  safety  of  this  method  for  both  intradermal  and
intratumoural vaccinations (Yamanaka et al. 2005, Yamanaka et al. 2003). Finally DCs may
also be fused with cultured autologous glioma cells and further injected intradermally. This
approach has been shown to be safe, resulting in partial regression of the tumour mass in
some cases (Kikuchi et al. 2001).
All of the above described gene therapy approaches for GBM have their own distinct
advantages and disadvantages. Generally, gene therapy strategies have proved to be safe
and well tolerated in GBM clinical trials, nevertheless the efficacy, despite promising pre-
clinical experiments, remains inconclusive. The reasons for the failures were mainly
attributed to inefficient gene delivery and gene transfer, rather than to the gene therapy per
se. Currently, interest has shifted towards multi-modality treatments, which combine
several gene therapy approaches at once. This may be the key in the future, and finally find
a way to combat GBM and also perhaps other malignant cancers.
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3 Aims of the study
The general aim of this study was to develop a large animal glioblastoma model for testing
delivery approaches for therapeutic molecules as well as to investigate malignant glioma
gene therapy applications of 15-lipoxygenase-1.
More specifically, the aims of this study were:
I) To assess the usefulness of VX-2 brain tumour model for testing of local delivery
of drugs.
II) To develop a rabbit malignant glioma model based on lentivirus mediated AKT
and RAS expression.
III) To investigate the effects of 15-lipoxygenase-1 on tumourigenesis and its
applications for gene therapy of glioblastoma multiforme.
IV) To evaluate whether the combination of HSV-tk suicide gene therapy with 15-
lipoxygenase-1 gene therapy could improve the survival and efficacy of
malignant glioma therapy.
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4 Materials and Methods
The  materials  and  methods  used  in  this  study  are  summarized  in  Tables  (3-7),  and  in
Figures 8 and 9. Detailed descriptions are provided in the original publications (I and III)
and in the manuscripts (II and IV).
Table 3. A summary of the methods used in this study
Method Description Used in
Viral vector production Adenoviral vector production
Lentiviral vector production
I, III, IV
II
Cell culture Cell line culture
Primary cell isolation and culture
Viral vector transduction
III, IV
II
II, III
In vitro experiments 15-LO-1 activity assay
mRNA isolation and Northern hybrydisation
PCR
Lipid peroxidation assay
Caspase-3 enzyme activity assay
III
III
III
III
III
Ex vivo experiments VX-2 tumour cell preparation
Stem cell isolation
I
II
In vivo experiments Anesthesia, sacrifice, tissue collection
Fixation, embedding, sectioning
Stereotactic injections to rabbit brain
Stereotactic injections to rat brain
Tumour cell implantation in rabbit brain
Stem cell implantation into rabbits brain
Tumour cell implantation in rats brain
Tumour resection
Re-passaging of the tumour
Magnetic Resonance Imaging in rabbit
Magnetic Resonance Imaging in rat
Gene transfers into mice via tail vein
I-IV
I-IV
I
III, IV
I
II
III, IV
I
II
I, II
III
III
Immunological methods Immunohistochemistry I-IV
Statistical analysis Kaplan-Mayer log rank test
One-way ANOVA
I, III, IV
III
Table 4. A summary of the cell lines used in this study
Cell line Description Origin Used in
VX-2 tumour pieces Epidermal carcinoma National Cancer Institute
Frederick (Maryland, USA)
I
293 Human embryonic kidney
cell line containing the left
end of human adenovirus 5
ATCC CRL-1573 III
RAW264.7 Mouse macrophage cell line ATCC TIB-71 III
BT4C Rat glioma cell line kind gift from Prof. Rolf
Bjerkvig (Bergen,
Norway)
III, IV
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Table 5. A summary of the animal models used in this study
Animal model Description Origin Used in
VX-2 tumour model VX-2 carcinoma implanted
into rabbit brain
(Carson et al. 1982a) I
Stem cell rabbit model Stem cells transduced with
oncogenes implanted into
NZW rabbits
II II
BT4C/BDIX BT4C rat glioma cells
injected into BDIX rat (Sandmair et al. 1999a)
III, IV
Table 6. A summary of the vectors used in this study
Vector Description Used in
Ad-LacZ
Recombinant adenovirus containing E. coli
–galactosidase under CMV enhancer and chicken
–actin promoter
I, III
pTomo H-RasV12 Recombinant Cre-loxP-controlled lentivirus
containing human Ras under CMV promoter
II
pTomo HA-AKT Recombinant Cre-loxP-controlled  lentivirus
containing human AKT under CMV promoter
II
AdCre Recombinant adenovirus containing Cre
recombinase under CMV promoter II
simp53 Recombinant lentivirus containing mouse p53
siRNA under CMV promoter II
Adh15-LO-1 Recombinant adenovirus containing human 15-
LO-1 under CMV promoter
III, IV
AdHSV-tk Recombinant adenovirus containing HSV-tk under
CMV promoter
IV
Table 7. A summary of the antibodies used in this study
Antibody Description Application Distributor Used in
CD31 mouse anti-human IHC Dako Cytomation I, II
Ki-67 mouse anti-human IHC Dako Cytomation I, II
-galactosidase mouse anti-bacterial IHC Promega I
HA tag mouse anti-HA tag IHC Nordic Biosite II
flag M2 mouse anti-flag M2 IHC Sigma-Aldrich II
p53 mouse anti-human IHC Santa Cruz II
GFAP mouse anti-mammalian IHC Abcam II
15-LO antibody
CheY
rabbit polyclonal anti-human IHC (Sigal et al. 1990) III
Caspase-3 rabbit polyclonal anti-human IHC Promega III
CD34 goat polyclonal anti-rat IHC R&D IV
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Figure 8. Study protocol in III (A) and IV (B). In both groups, the tumour cells were inoculated
on day one and the rats received multiple injections of viral vectors on days 15 and 16. In study
III,  the  animals  were  scanned  with  MRI  on  days  14,  28  and  42  after  inoculation  (A).  The
animals from study IV received additional  GCV therapy which was commenced on day 20 and
continued for 14 days (B).
Figure 9. Multiple  site  injection  technique  for  AdHSV-tk  (A)  and  Adh15-LO-1  (B).  Depth  is  in
milimetres from the bregma level.
A
B
BA
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5 Results
5.1 VX-2 BRAIN TUMOUR MODEL (I)
The purpose of this study was to determine whether the VX-2 rabbit brain tumour model
could  mimic  the  true  clinical  situation  and  be  useful  in  evaluating  novel  therapeutics.   A
total of 1.8×103 viable  cells  were  implanted  into  26  New  Zealand  White  rabbits  (5  mm
caudally and 6 mm right from the sagittal suture into 2-mm depth from the dura surface).
Animal survival was monitored with (n=9) or without (n=13) resection and the tumour
growth  was  examined  with  MRI  twice  a  week.  The  animals  in  the  non-resected  group
survived 17 to 36 days, whereas the survival of animals in resected group ranged from 29 to
51 days. The median survival in the non-resected group was 23 and in the resected group it
was 37 days, i.e. 60.8% prolongation in survival of the resected animals compared to the
non-resected controls. Kaplan-Mayer analysis revealed a highly significant difference
between the non-resected and resected groups (p< 0.001).
Figure 10. The Kaplan–Meier logrank analysis  with Bonferroni's  post  hoc test  verified a highly
significant difference in survival of nonresected and resected animals (p<.001).
Histologic analysis of VX-2 brain tumours revealed that the tumours were characterized
by large central necrotic areas indicative of the presence of a hypoxic environment similarly
to the situation in high grade brain tumours. VX-2 tumour cells exhibited highly aggressive
and invasive growth, similar to human glioblastoma. The tumour borders of VX-2 tumours
were ill-defined as they are intermingled with normal brain cells. The invasive nature of the
VX-2 brain tumours is believed to contribute to the limited long term therapeutic effect of
the tumour resection, similarly to clinical experience with high grade glioma patients,
where the infiltrating tumour cells are responsible for a recurrent disease within the site of
the previously resected tumour. Staining for proliferation marker Ki-67 demonstrated that
VX-2  tumours  were  highly  proliferative  with  a  number  of  positively  stained  proliferating
cells being detected in the tumour area while the CD31 immunostainings confirmed that
VX-2 tumours were highly angiogenic.
Four animals underwent surgery in combination with AdLac-Z gene transfer into three
independent sites (1.05×109 VP in 7.5 μl). Upon investigation of the efficiency of adenovirus
vector mediated gene transfer with commonly used local stereotactic injections into the
walls of the resection cavity, we detected LacZ positivity in all animals at least at 2 injection
sites with <5% efficiency. LacZ expression was detected both in tumour cells and in cells of
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the brain parenchyma around the injection sites. The majority of the transduced cells were
normal CNS cells.
5.2 RAS, AKT AND P53 siRNA MEDIATED ONCOGENESIS IN RABBIT (II)
The aim of this study was to investigate the utility of lentivirus vector mediated oncogenic
transformation for establishing rabbit malignant glioma. NSCs were harvested from
hippocampal and subventricular areas from newborn rabbit pups (Castren et al. 2005,
Clarke et al. 2000). Constitutively active AKT and H-Ras oncogenes were introduced using
lentiviral  vectors  at  MOI  3  together  with  Adeno-Cre  at  MOI  30  and  lentivirus  carrying
mouse p53 siRNA at MOI 30. The transduced NSCs were implanted on the following day
into 10 NZW rabbits, and this resulted in tumourigenesis in one animal. The growth of the
tumour was followed with MRI until animal sacrifice on day 141.
To determine whether lentiviral driven oncogenesis was successful,
immunohistochemistry was used to detect the HA tag and Flag M2 i.e. markers of AKT and
H-Ras  transgenes  respectively.  AKT  and  Ras  were  present  in  the  tumour  cells,  which
expressed either one or both proteins at the same time, thus revealing the heterogeneity of
the tumour cell population. Additionally, strong expression of GFAP was observed, in line
with the results seen in the majority of ganglioglioma subtypes (Zhang et al. 2008,
Karremann et al. 2009).
    Upon further histological analysis, it was revealed that the tumour exhibited
resemblance  to  a  benign  grade  II  ganglioglioma.  The  tumour  displayed  the  emergence  of
ganglion and glial cells, that are large, rounded, often multinucleated or characterised with
nuclear atypia. Interestingly, similarly to the situation in many human gangliogliomas
(Zhang et al. 2008), microcalcification was observed within the tumour area. Moreover,
H&E staining revealed the presence of tumour cells around the vessels within the tumour
area. The PAS-positive pattern was found on the vessel wall of the intratumoural vessels,
while CD-31 positive cells were observed on the luminal surface of the vessels, i.e. evidence
of vascular co-option. Additionally, a dense network of small branching capillaries was
detected. Curiously, unlike in typical low grade gangliogliomas, numerous proliferation
figures, were found, as indicated in the Ki-67 staining. Usually, less than 5% of tumour cells
express Ki-67 in grade II gangliogliomas (Rousseau et al. 2006), thus we believe that the
high number of proliferating cells may have been an indication of a progression to an
anaplastic stage of the tumour (Rogojan, Olinici 2008).
5.3 ROLE OF 15-LO-1 IN GLIOBLASTOMA MULTIFORME TUMOUR
PROGRESSION AND SURVIVAL (III)
The aim of this study was to clarify the anti-tumourigenic effects of 15-LO-1, in particular
its potential pro-apoptotic effects. This is apparently the first time that the effect of 15-LO-1
has been evaluated in the syngeneic rat model of malignant glioma.
In vitro functionality of Adh15-LO-1 virus was verified by RAW264.7 mouse macrophage
transduction and measured via the levels of 13-HODE produced. In vivo expression of 15-
LO-1 protein was confirmed by mRNA detection in liver and spleen 3 and 7 days after tail
vein injection. The mRNA could also be detected in kidneys, lungs and aorta.
Immunochistochemical analysis confirmed 15-LO-1 protein expression in liver and spleen,
but not in lungs, kidneys or aorta.
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Figure 11. Tumour volumes in Adh15-LO-1 treated and control animals two weeks (A) and four
weeks (B) after BT4C cell implantation and gene therapy. (C) Kaplan-Meier survival analysis of
Adh15-LO-1 gene therapy. Rats after implantation of BT4C cells were treated with Adh15-LO-1
(n=12) or followed up as control animals (n=5). The median survival of the treated and control
groups were 42.5 days and 36.0 days, respectively (p=0.001).
Lipid peroxidation, as analysed in mouse liver, showed a significant increase of
oxidative products i.e. malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) in Adh15-
LO-1 treated animals (3,5 fold increase at day 3; 2,0 fold increase at day 7). Apoptosis was
detected via two methods: immunohistochemical detection of the active form of caspase-3
and enzymatic activity of caspase-3 from tissue homogenates. A tendency towards an
increased  amount  of  positively  stained  cells  was  noted  in  the  liver,  although  the  results
were statistically non-significant. However, there was a dramatic 32-fold increase in
caspase-3 enzymatic activity in the liver samples of Adh15-LO-1 treated animals seven days
after gene transfer.
The effect of 15-LO-1 expression on malignant glioma tumourigenesis was investigated
in the BDIX rat model. The rats were divided into two groups, one group received Adh15-
LO-1 gene therapy (n=12) and the control group which did not receive any treatment (n=5).
Tumour volumes were visualised by MRI one day before gene transfer as well as two and
four weeks afterwards. There was no significant difference in tumour size, yet a tendency
for smaller tumours in the Adh15-LO-1 group was clearly visible, evidence that the tumour
growth was slowed down but not completely suppressed. Nevertheless, the Adh15-LO-1
treatment resulted in significant prolongation of animal survival as the median survival
time was 42,5 days in comparison to 36,0 days in control animals (p=0,001).
5.4 15-LO-1 AND HSV-TK COMBINATION GENE THERAPY (IV)
The purpose of this study was to investigate whether the combination of 15-LO-1 and HSV-
tk  gene  therapy  could  improve  the  survival  in  the  rat  model  of  malignant  glioma.  The
combination  gene  therapy  group  consisted  of  13  animals,  while  8  animals  were  in  the
control group. No statistically significant difference in survival between combination
therapy and control groups was found (p=0.76). The median survival times upon 15-LO-1
and HSV-tk treatment were 30.0 days and 37.0 days for the control group.
Usually, transplantable tumours in rodents form solid nodules at the injection site which
compress  rather  than  invading  the  surrounding  brain  regions.  In  contrast,  the  BT4C  rat
glioma model is characterized by its evident invasiveness and thus is much more
appropriate for trials of novel therapies for GBM. In this model, there are two mechanisms
involved in the invasive process. Some of the migratory cells invade healthy brain
parenchyma  individually,  by  propulsion  and  elongation  of  leading  pseudopods.  Others
however,  invade  as  a  group  of  cells  by  means  of  chain  migration,  which  is  very  effective
penetration  mechanism  and  it  confers  on  these  cells  a  high  metastatic  capacity.  Those
mechanisms  of  tumour  migration  were  prominent  in  both  animal  groups.  However,  the
animals in the combination treatment therapy group, displayed higher invasive activity of
malignant cells, with two animals showing profound malignant invasion into the
contralateral hemisphere.
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Figure 12. Kaplan-Meier survival analysis of Adh15-LO-1 and AdHSV-tk combination gene
therapy.  Rats  after  implantation  of  BT4C  cells  were  treated  with  Adh15-LO-1  and  AdHSV-tk
(n=13) or followed up as control animals (n=8). The median survival of the combination and
control groups were 30.0 days and 37.0 days, respectively (p=0.76).
Microscopic evaluation revealed that in the combination therapy cohort, the treatment
induced a shift in the glioblastoma tumour phenotype toward enhanced migration and
healthy tissue infiltration, represented not only by single cell infiltration but also by the
formation of multiple satellite tumours. Furthermore, those satellite tumours were not only
present  surrounding  the  bulk  of  the  primary  tumour,  but  also  had  migrated  far  into  the
healthy brain parenchyma. Interestingly, many of the satellite tumours were associated
with blood vessels. CD34-PAS dual staining revealed that the tumour cells had co-opted
pre-existing vessels to supply them with oxygen and nutrients. It seems that co-option of
the host vasculature was a compensatory mechanism evoked to counteract the stress
exerted by combination therapy. Moreover, tumour cells ensheathed preexisting vessels
particularly in the massive vascular plexus present in the brain tissue to allow them to grow
rapidly and invade healthy tissue without the need of neovascularisation. This kind of
migration pattern is similar to the growth pattern of GBM in humans, which often invades
healthy areas along the host vasculature.
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6 Discussion
6.1 DEVELOPMENT OF LARGE ANIMAL MODEL OF MALIGNANT GLIOMA
(I, II)
It is clear that cell culture systems are unsatisfactory when it comes to prediction of the
outcome  of  therapy.  Evidently,  as  cells  are  grown in vitro, they are removed from the
normal context of the brain and they undergo non-physiological selective pressures instead
of addressing the pressures of tumour microenvironment such as the role of ECM, immune
system or vasculature. Animal models are indispensable in cancer research, yet there is no
model that mimics all the features of human GBM. Ideally, brain tumour models should be
of glial origin and bear a resemblance to the histopathology of human GBM. Moreover it is
crucial that the tumour is non-immunogenic and has a highly reproducible growth pattern.
For  studies  aiming  at  evaluation  of  possible  therapies,  it  is  also  critical  that  host  survival
time is sufficient to permit treatment and to evaluate its efficiency.
Another essential issue that needs to be addressed for successful translation of novel
therapeutics is infiltration of surrounding healthy tissue that precludes total surgical
debulking.  In  humans,  invasive  cells,  which  are  characterized  by  high  plasticity  and
resistance to therapies will often give rise to a recurrent tumour, which in the great majority
of the cases arises adjacent to the resection margin and leads to a fatal outcome. These
migratory tumour cells temporarily exit the cell cycle during migration, making them
resistant to therapies that target dividing cells (Berens, Giese 1999). It is unclear the extent
to which currently existing therapies reach those cells and influence their survival.
Moreover, malignant cell infiltration into healthy brain parenchyma points to the existence
of specific interactions between cancer cells and the microenvironment that could be a
promising new target for therapy. The scarcity of modelling systems that reflect the brain
tumour infiltration as well as allowing for the direct targeting of malignant cells is a severe
problem. It is tempting to speculate that the future of tumour therapies may lie in targeting
these migratory cell populations and hence emphasizing the need for a model that allows
for tumour cavity exposure and treatment of the newly uncovered tissue.
Finally, the lack of an easily available large resectable brain tumour animal model may
be one of the reasons why gene therapy modalities have failed once translated from rodent
models to human patients, as the preclinical and clinical treatment strategies vary
extensively. Gene therapy experiments on rodent models are commonly performed using
direct stereotactic intratumoural injections (Mizuno, Ryuke & Yoshida 2002, Tyynela et al.
2002). Nevertheless, the clinical delivery of gene therapy varies significantly. For example,
in the Cerepro study (Ark Therapeutics Group plc), the patients underwent craniotomy for
radical resection using routine neuronavigation. Viral vectors were administered directly
into  the  healthy tissue of  the  wound bed after  tumour resection and the  patients  received
multiple injections, depending on the size of the tumour cavity (Immonen et al. 2004).
Unfortunately, basic research commonly disregards the fact that resection may change the
course of therapy. Surgical intervention not only affects the application route of further
treatments, but it is believed that it may even change the efficacy of adjuvant therapies (Ng,
Wan & Too 2007, Stewart 2002, Barker et al. 2001)  Last but not least, models that enable
surgical debulking offer not only the possibility of initial tumour treatment but also
intervention during disease recurrence. Therefore, a widely available, large animal
malignant glioma model, such as the rabbit GBM model, could be a significant benefit and
complement studies carried out in rodent models.
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6.1.1 VX-2 brain tumour model mimics clinical treatment of malignant glioma (I)
Tumour resection is the standard, yet critical, therapeutic intervention.  Utilizing an animal
model that would allow assessment of innovative treatment approaches in combination
with gross surgical resection could improve the prediction of the therapy outcome in
humans. VX-2 is an anaplastic rabbit carcinoma, which once implanted into the cortex
grows and displays several characteristics of invasive brain tumours (Carson et al. 1982b).
This study present evaluated the suitability of VX-2 model for gene delivery testing.
VX-2 tumours were implanted into immunocompetent rabbits, a crucial factor since the
model should closely resemble the immunological conditions that exist in brain tumour
patients. Moreover, since these animals have an intact immune system, they are suitable of
evaluating therapies that enhance the host immune responses against cancer, unlike most
murine models.
It was found that VX-2 tumours displayed invasive characteristics similar to human high
grade brain malignancies i.e. they were highly infiltrative and demonstrated a diffuse
spread of malignant cells into non-neoplastic parenchyma. It should be recognized
however, that the infiltrative growth patterns were qualitatively different than those seen in
humans. The VX-2 tumour typically invades healthy tissue in small clusters of cells,  while
in  glioblastoma,  which  is  the  most  aggressive  of  human  brain  tumours,  single  malignant
cells  are  scattered  into  the  surrounding  brain  parenchyma.  Nevertheless,  infiltration  of
surrounding  healthy  tissue  complicates  total  surgical  debulking  in  VX-2  tumours  as  in
human brain tumour patients, where it usually recurs within a few centimeters of the
resection margins from a residual pool of invasive cells. Histological analysis of VX-2 brain
tumours revealed that the tumours were characterized by large central necrotic areas which
would  be  suggestive  of  the  presence  of  a  hypoxic  environment  similar  to  the  situation  in
human GBM. Additionally, was demonstrated that MRI could be employed for in vivo
monitoring of tumour growth and its recurrence. The efficiency of adenovirus vector
mediated gene transfer was investigated by stereotactic injection into the wound bed after
tumour  resection,  achieving  successful  marker  gene  expression.  The  VX-2  rabbit  brain
tumour model could thus facilitate the development of innovative local gene delivery
approaches and bring closer the days of efficient gene transfer in the clinical setting.
Importantly,  this  model  also  could  be  used  to  study  the  efficiency  and  delivery  methods
directed at satellite lesions.
The VX-2 rabbit brain tumour model has proven to be technically straightforward to
develop and it is highly reproducible. However, it should be recognized that the main
pitfall with this model is that it does not originate from glial cells. Nonetheless, the VX-2
model provides the possibility to test locally delivered promising therapeutics in
combination with tumour debulking surgery, which is a crucial aspect of clinical treatment
protocols. In this way, it can complement studies carried out in rodent models and facilitate
translation to clinical success.
6.1.2 Development of a rabbit glioma model based on lentivirus driven oncogenesis (II)
Lentiviral vectors are an excellent tool in molecular biology since they have the possibility
of achieving stable and long term expression of transgenes. These vectors have been
utilized to study the role of various oncogenes in malignant transformation, but the
lentiviral oncogene transfer has also opened the prospect to create novel animal models by
manipulation of molecular pathways. This present study investigated the utility of
lentivirus mediated oncogenic transformation for establishing a rabbit malignant glioma
model.
The previous study by Marumoto and coworkers proved that the transfer of AKT and H-
Ras oncogenes using Cre-LoxP controlled lentiviral vectors into transgenic mice brain
cortex  resulted  in  tumour  formation  but  with  a  low  ratio  (Marumoto  et  al.  2009).  The
authors  concluded  that  this  phenomenon  could  be  related  to  the  absence  of  NSCs  in  the
cortical area, as a similar experiment revealed a significantly higher probability of
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tumourigenesis upon injection of oncogene carrying vectors into hippocampus or
subventrical zones.  Thus, to increase the chance of oncogenic transformation, yet ensure a
location  favourable  for  tumour  resection, ex vivo transduced NSCs were injected into
cortical brain of NZW rabbits.
In the present study, one out of ten rabbits developed a tumour and the presence of AKT
and H-Ras was verified with immunostaining. However, it was not possible to demonstrate
indisputably the blockade of p53 expression. Nevertheless, a high number of Ki-67 positive
cells could be detected. It has been previously shown that the Ki-67 expression can increase
in  the  tumours  carried  by  p53  heterozygous  mice  in  comparison  to  mice  normally
expressing p53 (Marumoto et al. 2009). Thus, the high number of Ki-67 expressing tumour
cells  may  be  an  indirect  indication  of  reduced  activity  of  p53.  Interestingly,  unlike  in  the
previous study where injection of AKT and H-Ras into NSCs containing areas in p53
heterozygous mice gave rise to glioblastoma-like tumours, AKT, H-Ras and p53 siRNA
transduced rabbit stem cells induced the formation of ganglioglioma. Ganglioglioma is a
grade  II  glial  tumour,  occuring  mostly  in  patients  younger  than  30  years  (Miller,  Lang  &
Epstein 1993, Mpairamidis et al. 2008). Thus, contrary to the results obtained by Marumoto
(Marumoto et al. 2009), the tumourigenicity of our rabbit model remained low, in spite of
the use of ex vivo cultured NSCs.
One  of  the  reasons  for  decreased  tumourigenicity  may  be  the  critical  role  of  the
microenvironment. Hippocampal and subventrical regions may provide the factors
necessary for the growth of stem cells that are otherwise absent in the cortex. Another
reason for the low tumourigenic potential of NSCs may be possible changes that could have
occurred during ex vivo culture. NSCs were obtained from hippocampus and lateral
ventricle wall from newborn pups as described by Clarke and Castren (Castren et al. 2005,
Clarke et al. 2000). To minimize the risk of stemness loss, the NSCs were transduced upon
their  second  passage  and  implanted  into  the  adult  rabbits’  brain  on  the  following  day.
Nevertheless, the possibility of changes that could occur in the NSCs during cell cultivation
prior  to  the  gene  transfer  cannot  be  excluded.  Finally,  it  was  not  possible  to  confirm  the
efficiency of the gene transfers as the transduced stem cells differentiated rapidly and
needed to be implanted in vivo as soon as possible. Thus, one cannot be certain that the low
tumourigenicity was not due to transduction inefficiency. Nevertheless, one pilot in vitro
experiment showed that rabbit pup NSCs were easily transduced and the combined rate of
the transduction for all the viral vectors was above 80%. Unfortunately, it was not possible
to determine the transduction rates for each single vector, nor confirm whether the cells
were transduced with one or more vectors at the same time. Interestingly, upon tumour
histology expressions of either AKT, or H-Ras or both were detected in the tumour cells, i.e.
evidence that the tumour was composed of heterogenous cell populations.
This study demonstrated that transformation of NSCs from newly born rabbit pups
resulted in the formation of ganglioglioma, while the previous study utilizing direct
injection transformed adult mice NSCs into glioblastoma-like tumours. Thus, an interesting
question arises of whether the age of NSCs could influence the tumourigenic properties of
NSCs upon malignant transformation.
6.2 ANTI-TUMOURIGENIC EFFECTS OF 15-LIPOXYGENASE-1 IN RAT
MODEL OF MALIGNANT GLIOMA (III)
Gene  therapy  is  a  powerful  technique  in  molecular  medicine  that  allows  for  the
treatment of wide array of diseases, including GBM. The genes inducing apoptosis and
inhibiting angiogenesis in glial cells are of particular interest.  15-LO-1 is a multifunctional
enzyme able to produce a vast number of metabolites with diverse bioactivities. The levels
of 15-LO-1 expression have been determined in a variety of normal and cancer tissues and
its levels are significantly decreased in many carcinomas (Kim et al. 2006, Sasaki et al. 2006,
Wu et al. 2003, Shureiqi et al. 2001), which may suggest that 15-LO-1 possesses some anti-
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tumourigenic  properties  and  therefore  is  suppressed  in  the  process  of  carcinogenesis.  15-
LO-1 is known to take part in the process of apoptosis. However, there are controversial
results about its role in the regulation of apoptosis and tumour growth (Furstenberger et al.
2006, Nie et al. 2001).Therefore this study was aimed at clarifying the effect of 15-LO-1 on
cellular apoptosis and testing whether it could represent a new treatment strategy for GBM.
In vitro studies with the RAW264.7 macrophages proved that the recombinant Adh15-
LO-1 virus could produce enzymatically active human 15-LO-1 protein. Gene transfers into
mice via the tail vein resulted in the expression of the transduced human 15-LO-1 mRNA in
various tissues. 15-LO-1 and its reaction product 13(S)-HODE are known to be pro-
apoptotic and anti-tumourigenic in in vitro and  also in vivo in some cancer types. In this
study,  it  was  found that  a  high level  of  15-LO-1 expression induced lipid peroxidation in
mouse  livers,  detected  as  MDA  and  4-HNE.  These  lipid  peroxidation  end  products,
particularly 4-HNE, have been shown to induce apoptosis in several different cell lines via
caspase activation (Liu et al. 2000, Ji et al. 2001, West et al. 2004, Ferrington et al. 2006). This
study showed that over-expression of 15-LO-1 induced increased synthesis of lipid
peroxidation end products MDA and 4-HNE, followed by the induction of caspase-3
mediated apoptosis, i.e. support for a pro-apoptotic role for 15-LO-1 and its reaction
products.
The reason for the use of Adh15-LO-1 gene therapy for GBM relies on the idea that pro-
apoptotic treatment strategies offer the prospect of developing new therapeutic approaches
(Shinoura, Hamada 2003). It was also shown that expression of the activated form of
caspase-3 was a good prognostic factor in cancer patients (Kobayashi et al. 2007), thus it is
hypothesized that this treatment may target the glioma apoptotic pathway in an effective
manner. Moreover, cells with increased expression of caspase-3 were shown to be more
sensitive to radiation treatment (Tsurushima et al. 2007). Additionally it is possible that
such a complex molecule as 15-LO-1 may exert additional antitumourigenic activities on
GBM. Previous work by our group has shown that 15-LO-1 possesses strong anti-
angiogenic activity, which taken together with the fact that malignant gliomas are among
the most vascularised tumours in humans, makes it a good target for combating this
malignancy (Norden, Drappatz & Wen 2008).
As far as is known, this is the first time that 15-LO-1 has been demonstrated to
significantly  prolong the  survival  in  BDIX rat  malignant  glioma model.  It  was  found that
Adh15-LO-1 treated animals lived significantly longer than the control group and they
showed a tendency to delay tumour growth. Thus, it is concluded that 15-LO-1 seems to be
a promising candidate for gene therapy of GBM.
6.3 COMBINATION OF 15-LO-1 AND HSV-TK GENE THERAPY INDUCES
METASTATIC PHENOTYPE (IV)
The several successful clinical trials for malignant glioma treatment conducted in recent
years have drawn attention to the potential of suicide gene therapy strategies. In particular,
therapies utilising HSV-tk have been widely tested and shown to be beneficial for patients
(Wirth et al. 2009, Immonen et al. 2004). Nevertheless, it is believed that no single treatment
will be able to combat this highly heterogenous and aggressive tumour. Hence it is believed
that suicide gene therapy could be further enhanced by combination with other treatment
modalities in order to improve its efficiency. Previous research has proved that 15-LO-1 is a
multifunctional enzyme that inhibits the angiogenesis process on several stages (Viita et al.
2008) as well as producing metabolites that provoke apoptosis (Kim et al. 2006, Sasaki et al.
2006, Wu et al. 2003, Shureiqi et al. 2001). Thus, it is concluded that 15-LO-1 might act
through two independent mechanisms and its anti-angiogenic effects could be additionally
complemented with proapoptotic properties making it an interesting and promising
molecule for combination gene therapy studies.
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No statistically significant difference was observed in survival between control group
and combination therapy of HSV-tk and 15-LO-1. Interestingly, our combination therapy
treatment induced a shift in glioblastoma tumour phenotype towards enhanced migration
and  healthy  tissue  infiltration.  Apart  from  single  cell  infiltrations  into  normal  brain
parenchyma, clusters of glioma cells seemed to migrate along the vasculature and were
seen around blood vessels in the normal parenchyma forming multiple satellite tumours.
Moreover, the co-option of the host vasculature may be one way that the tumour attempts
to respond to the combination therapy. Large areas were identified where the tumour cells
ensheathed preexisting vessels and traveled along them to invade healthy tissue. In
particular, the massive vascular plexus present in the brain tissue seemed to be a favourable
place  for  invasion.  Those  results  suggest  that  some  of  the  neoplastic  cells  had  adapted  to
being able to evade gene therapy treatment by escaping from the original tumour site.
This  data  is  in  line  with  other  reports,  suggesting  that  some  cancer  therapeutics,  in
particular anti-angiogenic drugs, may elicit tumour adaptation and its progression to
metastatic phenotype. The increased invasiveness after anti-angiogenic therapy was first
time described in mouse models of orthotropic GBM, where neovascularisation was slowed
down with agents such as antibodies or SU5416 inhibitor affecting VEGF signalling
(Rubenstein et al. 2000, Ebos et al. 2009). Increased invasiveness and profound vessel co-
option were reported in those studies. In line with the in vivo results came the data from
clinical trials, where some of the studies indicated pro-invasive adaptation in humans in a
subset of GBM patients who developed multifocal recurrence of tumours upon anti-VEFG
therapy with bevacizumab (Bergers, Hanahan 2008).
Nevertheless, it is very tempting to speculate that the known anti-angiogenic properties
of 15-LO-1 are not per se the only possible reason for the increased invasiveness seen with
the combined therapy. Malignant cells are highly plastic and hence, it is probable that any
potent drug intervention, that deteriorates the conditions for cancerous growth may
stimulate  malignant  glioma  cells  to  migrate  and  invade  healthy  areas.  In  conclusion,  it  is
possible that the detected increased migratory potential of glial cells resulted not only from
an anti-angiogenic property of 15-LO-1, but a combined action mediated through several
molecular mechanisms all with powerful anti-tumourigenic activities, forcing the cells to
migrate in order to survive.
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7 Conclusions
Based on the present results, the following conclusions can be made.
I) The VX-2 model shows similarities in growth and pathology to aggressive brain
tumours and allows for tumour debulking and local application of therapeutic
agents into the walls of the resection cavity. Tumour resection significantly
improves the survival of animals, but the progression of the disease still leads to
death, mimicking the clinical reality in patients.
II) Lentiviruses  carrying  constitutively  active  AKT  and  Ras  oncogenes,  and  mouse
siRNA p53 when introduced into neural stem cells and intracranially implanted
into rabbit brain are able to initiate tumour formation. The histological features
and analysis of the tumour mimic closely benign grade II ganglioglioma type.
III) 15-LO-1 shows a clear tendency to decrease tumour volume and significantly
extends survival in the rat malignant glioma model, possibly via induction of
lipid peroxidation in tumours in vivo. The results suggest that 15-lipoxygenase-1
could be a potential new treatment gene for therapy for malignant glioma.
IV) 15-LO-1 and HSV-tk combination gene therapy does not inhibit tumour growth
and confers no survival benefits when compared to control. However, the
treatment induces a shift in the glioblastoma tumour phenotype towards one
with enhanced migration and healthy tissue infiltration.
To summarize, the results of this study demonstrate that the VX-2 model may be used for
testing  novel  drugs  and  delivery  routes  for  brain  tumours.  To  our  knowledge,  this  study
also proved for the first time that it is possible to induce glioma in rabbits with the use of
lentivirus transduced neural stem cells. Finally this study showed that 15-LO-1 is a
promising molecule capable of inhibiting glioblastoma growth and prolonging animal
survival.  Nonetheless,  when  combined  with  a  commonly  used  suicide  gene  therapy
strategy,  it  induces  a  shift  in  glioblastoma  tumour  phenotype  toward  one  with  enhanced
migration and infiltration of healthy tissue.
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Glioblastoma multiforme is the most 
malignant of brain tumours and it is 
one of the most fatal cancers in hu-
mans. This thesis aimed at develop-
ing a new model that would allow for 
tumor debulking and local applica-
tion of therapeutic agents. Addition-
ally, a new treatment approach based 
on 15-lipoxygenase-1 gene transfer 
was studied. The results demonstrat-
ed that it was able to prolong animal 
survival, although it may also induce 
cell migration upon combination with 
HSV-tk gene therapy.
